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Discovery, structure-function characterization and assessment of 
polyoxometalates as modulators of the DNA binding activity of the Sox-HMG 
family of transcription factors 
Abstract 
Aberrant expression of transcription factors is a frequent cause of disease yet drugs that modulate 
transcription factor protein-DNA interactions are presently unavailable. To this end the chemical 
tractability of the DNA binding domain of the stem cell inducer and oncogene Sox2 was 
explored in a high-throughput fluorescence anisotropy screen. The screening revealed a Dawson 
polyoxometalate (K6[Mo18O62P2]) as a direct and nanomolar inhibitor of the DNA binding 
activity of Sox2. [15N,1H]-Transverse relaxation optimized spectroscopy (TROSY) experiments 
coupled with docking studies suggest an interaction site of the Dawson 
polyoxometalate(K6[P2Mo18O62]) on the Sox2 surface that enabled the rationalization of its 
inhibitory activity. Detailed investigation on a panel of different transcription factors against an 
expanded set of various polyoxometalates revealed that the Keggin and Dawson class of 
polyoxometalates exhibit a marked dichotomy in their selectivity and inhibition potential of the 
Sox-HMG family of transcription factors. Dawson polyoxometalates modified with organic 
moieties were found to invariably amplify the inhibitory potency of the pristine “Dawson” 
scaffold against Sox-HMG members, while a commensurate change in selective discrimination 
of the HMG family members could not be observed. The functionalization effect of the Dawson 
scaffold in inhibiting the Sox-HMG family merits investigation in the future. Taken in its 
entirety, the polyoxometalates have expanded the repertoire of molecular scaffolds that render 
transcription factors chemically tractable and provide strategies for the development of drugs that 
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1.1 Gallery of small molecule inhibitors of 
transcription factors namely Estrogen receptor 
alpha (Disulfide benzamide), STAT3 (Stattic,, 
galliellalactone), AIF (Aurin tricarboxylic 
acid), HIF-1 (Echinomycin), p53 (Nutlin 3) 




1.2 A) The HMG box of the Sox family of proteins is 
primarily a three-helix bundle that binds to the 
minor groove of the DNA inducing a ~70º 
bending as observed in the case of Sox2 
(PDB:1GT0).  
 
B) An unrooted neighbor joining phylogenetic 
tree generated using MAFFT and visualized 
using splitstree showing the different 
groupings of representative  human Sox-HMG 
domain sequences (1-3). 
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1.3 A) Conventional chemotherapeutic agents target 
the somatic cells that form the bulk of the 
tumor but do not target the CSCs which would 
form a small fraction of the tumor mass 
causing a relapse of the tumor. By selectively 
targeting CSCs using novel drugs that target 
aberrant transcription factors involved in 
cancer stem cell formation, it would be 
possible to treat aggressive tumors.  
 
B) Sox2 expression universally marks embryonic 
and neural progenitor stem cells. A 
hypothetical Sox2 inhibitor either alone or in 
combination with other small molecules may 
have applications in directed differentiation of 




1.4 Ball and stick representation of some canonical 




A) Dawson [P2M18O62] n– 
B) Keggin [PM12O40] n– 
C) Preyssler[MP5W30O110] n– 
D) Lindqvist[M6O19]n– 
Where “M” is the transition metal atom and 
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based screening is that the fluorescently 
labeled DNA emits mostly depolarized light 
owing to its lower molecular weight as 
compared to the protein-DNA complex that 
emits partially polarized light because of its 
higher molecular weight. In a small molecule 
screening set-up, the difference in the intensity 
of polarized light can be measured to 
determine the bound and unbound states of the 
labeled DNA element with Sox2-HMG in the 
presence of the small molecules. 
 
40 
2.2 Overview of the fluorescence anisotropy based 
high-throughput screening for inhibitors of 
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3.1 A) Binding isotherm of Sox2-HMG with 1nM 
(FAM) CCND1. Increasing concentrations of 
Sox2-HMG increases the fluorescence 
anisotropy indicating Sox2-HMG DNA 
complex formation. Data represents the 
average of 3 independent titrations for a given 
concentration of Sox2-HMG in each of the 
reaction volumes.  
 
B) 80 nM Sox2-HMG and 1nM (FAM)-CCND1 
complex was allowed to reach equilibrium. 
The saturated complex was displaced using 





3.2 A) Assays are carried out in a 384-well microplate 
depicted schematically as a heatmap (color 
coded by anisotropy values. Red color 
indicates higher inhibition while yellow 
indicates relatively lesser inhibition). 
Compounds are added to each well, while the 
positive and negative controls were alternately 
added to the peripheral columns (column 2 and 
23) (4).  
 
B) Duplicate screens (Screen1 and Screen2) of the 
challenge and mechanistic diversity libraries 
revealed a Z’ factor larger than 0.6 indicating a 
sufficiently large signal window for robust hit 
identification.  
 
C) Z-scores from duplicate screens correlate well 
highlighting the reproducibility of the assay.  
 
D) Screening results are shown as histograms of 
composite Z-scores. Primary hits were defined 
as having a composite Z-score ≤ 3 and 
reproducibility < -0.98.  
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3.3 A) Fluorescence anisotropy assay showing that 
degradation products of K6[P2Mo18O62], 
namely, the phosphate ([HPO4]2-), the 
molybdate([MoO4]2-), and the Keggin 
phosphomolybdate ([PMo12O40]3-), do not 
disrupt a half-saturated Sox2-HMGDNA 
complex. Ball and stick representation of the 
Dawson and Keggin POMs.  
 
B) Small light gray spheres are oxygen atoms and 
the bigger dark spheres are transition metals 




3.4 A) Gel-shift assays using varying POM 
concentrations shows that K6[P2Mo18O62] 
selectively inhibits Sox2-HMG with an IC50 
value of 98.6 ±22.1 nM.  
 
B) Representative EMSA experiment showing 
dose-dependent titrations of K6[P2Mo18O62] 




(~50-70% )fraction bound) and 0.5nM Pax6 
and 1nM Pax6 DNA element (~50% fraction 
bound) reveals selective inhibition of the 
HMG-domain 
 
3.5 A) Limited proteolysis reveals that interaction of 
Sox2 with K6[P2Mo18O62] confers resistance to 
proteolytic digestion by trypsin.Sox2-HMG 
was incubated with trypsin in the presence 
(lanes 3-6) and absence (lanes 8-11) of the 
Dawson-POM K6[Mo18O62P2]). Reactions 
were stopped after different time points and 
analyzed by 4-12% SDS-PAGE. Molecular 
weight markers are added in lanes 1 and 7. 
Lane 2 contains the Sox2-HMG incubated for 
60min but not subjected to trypsin digestion.  
 
B) Thermal melting profiles ofSox2-HMG 
monitored in the presence of Sypro-orange 
with and without increasing concentrations of 
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4.1 Superimposed spectra of two-dimensional 
TROSY spectra of free Sox2 (pink) and Sox2 
bound to POM (blue).Each cross-peak 
represents a bonded N-H pair. The axes 
correspond to the chemical shifts of N and H 
atoms in ppm (parts per million).The peaks 
that undergo significant shifts upon complex 




4.2 The weighted change in chemical shift 
perturbations (∆δ = [∆δ2HN + (0.2∆δN)2]1/2 ) 
obtained from the 15N 1H TROSY experiments 
are mapped on the entire Sox2-HMG surface 
(1GT0). Residues which are significantly 
shifted are depicted. The colored spectrum bar 
displays the extent of NMR chemical shift 
perturbations in ppm. Unassigned residues are 
colored in gray 
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4.3 Changes in chemical shift (∆δ = [∆δ2HN + 67 
XIV 
 
(0.2∆δN)2]1/2 ) upon POM binding is plotted 
against the Sox2 amino acid sequence 
(numbered according to Sox2: 1GT0). 
Threshold windows indicating Significant (S), 
Moderate (M) and Low (L) chemical shift 
perturbations are depicted as straight lines. 
Green colored bars indicate residues which 
have been implicated in direct binding to POM 
based on docking studies. Residues that are 
unchanged in TROSY are indicated with an 
asterisk (*). Unassigned residues are colored in 
light blue and given arbitrary negative 
chemical shift values solely for data 
visualization purposes. Sox2-HMG residue 
sequences involved in DNA binding are 
colored in blue. Secondary structural elements 
like alpha helices are named and colored to 
distinguish whether they belong to the major or 
minor wing of the HMG domain. 
 
4.4 A) The lowest energy Sox2-HMG-POM complex 
structure from the Autodock searches shows 
the POM positioned within a pocket in the 
minor wing of the Sox2-HMG structure. Lys4, 
Arg5, Arg15, His63 and His67 are potentially 
involved in electrostatic or hydrogen bond 
interactions. Glu66 can donate hydrogen bond 
in a protonated form. Leu59, Leu62, Met7 and 
Val3 contribute to shaping the hydrophobic 
cavity. The Sox2 structure is shown as cartoon 
and the interacting amino-acids are shown as 
sticks. Dawson-POM K6[P2Mo18O62] is also 
shown in stick representation.  
 
B) Comparison of this docked model with the 
Sox2-DNA complex X-ray structure (1GT0) 
reveals that binding of POM to this site would 
directly interfere with DNA binding due to 
charge repulsion. The Sox2-DNA complex 
structure is shown as cartoon and the 
interacting amino-acids of Sox2 is depicted as 
sticks. The Dawson-POM K6[P2Mo18O62] is 



















   
4.5 A) Solvent accessibility per residue of DNA free 73 
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Sox2-HMG structure (PDB:1GT0) is plotted 
against the Sox2-HMG sequence and bars 
colored to depict their corresponding chemical 
shift perturbation category (NA-backbone 
unassigned residue).  
 
B) Interaction surface of Sox2-HMG colored by 
PM6 partial charges without and with docked 
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5.1 The regioselective (α1/α2) organic side chains 




5.2 A heatmap of the average residual DNA 
binding activity (‘value’ in %) of 15 different 
TFs against a panel of 15 POMs, clustered by 
their inhibition profiles (Red color indicates 
higher inhibition, while yellow color indicates 
relatively lesser inhibition). Keggin POMs 
exert lowered inhibition on the Sox-HMG 
members leading to the observation that the 
size of polyoxometalate is an important 
consideration in the inhibition of the Sox-
HMG family. Inhibitor compounds are color 
coded according to their polyoxometalate class 
as indicated in Table 5.1 (Dawson, Keggin or 
other simpler POMs like decavandate and 
sodium metatungstate).   
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5.3 A 3D bar plot depiction of the selectivity study 
of 15 TFs against a panel of 15 POMs from 
three-five independent experiments 
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5.4 A 2D bar plot  extract of figure 5.3 depicting 
the diverse and relatively selective inhibition 
effect of the Dawson-POM K6[P2Mo18O62]  
and KM633 (H3V10O28)  in inhibiting a panel 
of 15 TFs from three-five independent 
experiments 
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5.5 Multiple sequence alignment of the core 
HMG-domain of representative sox proteins 




members (Sox7 andSox18) and Sox2  in 6 out 
of 10 amino-acid positions proposed to be 
involved in K6[P2Mo18O62] binding with Sox2. 
Residues potentially involved in 
K6[P2Mo18O62] binding based on docking 
studies with Sox2 are indicated by red dots. 
Homologous Sox-HMG residue positions 
involved in POM binding that exhibit 
consistent differences between the Group F 
members (Sox7 andSox18) and Sox2 across 
the sequence alignment are indicated by an 
arrow. Numbering is based on Sox2 structure 
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6.1 A schematic representation of Sox2-HMG 
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The Earth is a mote of dust, suspended in a sunbeam, a very small stage in a vast cosmic arena. 
Think of the rivers of blood spilled by all those generals and emperors so that, in glory and 
triumph, they could become the momentary masters of one corner of this pixel, scarcely 
distinguishable from others. How frequent their misunderstandings, and how fervent their 
hatreds. Our posturings, our imagined self-importance, the delusion that we have of some 
privileged position in the universe, are all challenged by this point of pale blue light.1
                                                 






1.1 Introduction to transcription factors 
Transcription refers to the process in which information encoded in genomic DNA is faithfully 
transcribed into a complementary RNA sequence by the enzyme RNA polymerase 
(5).Transcription factors (TFs) are proteins that bind to DNA regulatory sequences either 
upstream or downstream of the transcription start site and control the transcription level of genes 
in association with the RNA polymerase through a variety of macro-molecular interactions (6). 
Transcriptional regulation is a complex event especially in eukaryotes as that involves the 
assembly of multi-protein complexes on core/proximal promoter or upstream enhancer modules 
that requires the co-operative assembly of co-activators, mediator, general and sequence specific 
transcription factors complexes (7).  The eukaryotic core promoter is typically a TATA-box of 
(~25% of eukaryotic genes have a TATA-box) the consensus sequence TATAAA that is found 
in the -25 region. RNA polymerase II and general transcription factors like TFIIA, TFIIB, 
TFIID, TFIIE and TFIIH constitute the basal transcriptional machinery responsible for 
transcription from the core promoter region(7). However, the level of transcription by RNAP II 
and the general TFs alone is usually low. In addition to regulation by core promoters, 
transcription can be regulated by enhancer sites that can be as far as a few kb or Mb from the 
transcription start site. Enhancers are part of the non-coding matter of the eukaryotic genome and 
insofar as in humans as many as 110,000 gene enhancer sequences have been identified(8). 
Enhancers exert spatial and temporal control over gene expression programs in specific tissues 
resulting in a regulated pattern of gene expression (8). Sequence specific transcription factors 
bind to the proximal promoter or enhancer module and serve to enhance the rate of the 
transcription of genes under its control. The specific recognition of cis-regulatory DNA elements 
by transcription factors is achieved by a multitude of factors like in vivo TF (transcription-factor) 
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concentration, the relative affinity of the TF towards it’s specific and non-specific sites, it’s co-
operativity with other protein-complexes, accessibility of nucleosomal DNA and not the least, 
like aspects of the presence/absence of epigenetic marks such as DNA methylation. Access to 
transcriptional templates in eukaryotes is also contingent on the displacement of nucleosomes 
from the promoter region of genes by chromatin remodellers and histone acetyltransferases (9). 
Biophysically, the readout mechanisms of TF’s can be thought to be a sum contribution of 
‘direct’ and ‘indirect’ readouts where the direct recognition by TF’s refers to major/minor groove 
base interactions characterized by hydrogen-bonding, hydrophobic and water-mediated 
interactions. By contrast, the indirect readout by TF’s refers to the global and local shape readout 
of the DNA characterized by bends, kinks, the groove widths and electrostatic potentials(10). 
Transcription factor-DNA recognition interfaces are characterized by a complex, interdependent 
network of bonding interactions, subtle alterations of which lead to substantially diverse binding 
preferences (11-13).A number of high-throughput measurements of protein-DNA interactions 
have significantly contributed towards a better understanding of the interaction landscape of a 
number of TF DNA binding structural classes(14-17). 
1.2 Diversity in transcription factor binding architectures 
A census of the human genome reveals the presence of about 2000-3000 sequence specific DNA 
binding transcription factors (~10% of the genome) belonging to many different structural 
classes (18). The eukaryotic genomes exhibit a diversity of TF structural classes with an array of 
diverse folds that have evolved strategies for interactions with DNA in a sequence specific 
manner. Based on available PDB structures of protein-DNA complexes, the SCOP family 
database identifies 70 SCOP superfamilies of DNA binding domains (10,19). For the sake of 
convenience, Remo Rohs et.al classify these superfamilies into four major groups based on their 
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overall secondary structure into mainly alpha, mainly beta, mixed alpha/beta and other multi-
domain proteins(10). Since some of the structure based classifications were arbitrary in 
classifying the mixed alpha/beta group of proteins, a recent classification pegs sequence-specific 
TFs into four major superclasses namely the basic, zinc-coordinating, Helix-turn-Helix and β-
scaffold based on phylogenetic analysis(20). Sequence specific TFs which don’t fall into the 
above three categories are referred to as the unclassified Others family(20). The largest metazoan 
transcription factor families are the C2H2 zinc fingers, the homeodomains, and the bHLH, while 
the plant kingdom is dominated by AP2, MADS box, WRKY and B3 families.  In humans, the 
basic superfamily consists of TFs which includes notable families like the bZIP (53 members) 
and the bHLH (110 members). Zinc-coordinating superfamily has prominent members like the 
C2H2 zinc finger (largest TF family in humans with 600 members), nuclear receptors (C4 zinc 
fingers), and the GATA family of TFs in humans(20). The helix-turn helix family in humans is 
most notably characterized by the homeodomain class of proteins which form a major chunk that 
utilizes the HTH structure. Examples of families that make use of HTH structures are the Hox, 
POU, Fox, IRF, Ets, RFX, HSF and E2F. The β-scaffold superfamily consists of TFs families 
like p53, RHR, NF-κB and the STAT family(20). Other human transcription factors which are 
conspicuous by their biological activities include the CBF/NF-Y and the simple tri-helical Sox-
HMG family.  
1.3 Transcription factors as attractive and challenging targets for 
small molecule modulation 
Transcription factors constitute an attractive subset of proteins for therapeutic intervention by 
small molecules, as aberrant expression of transcription factors is involved in a number of 
diseased states (21,22). Approximately 10% of the best selling drugs approved by the FDA 
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(Food and drug administration) are known to target transcription factors(23). At the structural 
level, transcription factors are modular proteins with usually a transcriptional activation domain, 
an oligomerization domain and a DNA binding domain. Modulator compounds targeted against 
transcription factors would have to prevent them from binding to one of their two primary 
molecular targets: protein or DNA (21). Traditional methods of targeting proteins rely heavily on 
non-high-throughput-screening approaches like structure-based drug design, in silico screening 
studies and high-throughput in-vitro assays. Small molecules targeted against ligand-binding/co-
factor binding/dimerization interfaces of transcription factors have been notably successful in the 
past(24). On the other hand the disruption of protein-DNA interfaces by targeting the DNA 
binding surfaces of the TFs poses a key challenge because of the highly electrostatic nature of 
protein-DNA interface, the lack of binding pockets, and the largely unstructured nature of the 
DNA binding domain in the absence of being bound to DNA(21,24). Targeting the DNA-binding 
surface of TFs can be a unique way of inhibition, in that it would not decouple the regulatory 
interactions of the other domains in the transcription factor. Such a targeting strategy cannot be 
accomplished by siRNA and morpholino based knock-down experiments. Several examples are 
abound in literature where small-molecule inhibitors have been successfully employed to 
physically interact and deactivate transcription factors by either targeting the activation domains, 
the ligand binding domains or the DNA binding domains (24-27).  
1.3.1 Targeting the ligand binding, activation and protein-protein interaction 
domain of transcription factors using small molecules 
The nuclear receptor family consisting of approximately 50 members is one of the most favorite 
targets of small molecule modulation as it intrinsically has a ligand binding activation 
domain(28). Notable nuclear receptor modulators are the selective estrogen receptor modulators 
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tamoxifen and fulvestrant, which are known to bring about tissue-specific ER agonistic or 
antagonistic activity(29).Small molecules like pyrimidine scaffolded molecules, benzenes and 
guanylhydrazones also target the ligand binding domain of Estrogen receptor and are known to 
affect subsequent SRC (steroid receptor co-activator) interactions(30-32). In the case of thyroid 
receptors, vinyl-aryl ketones covalently react with their activation domain and abrogate their 
binding interaction with thyroid receptor co-activators (33).β-aminoketones were also found to 
inhibit steroid receptor co-activator SRC2 from binding to thyroid receptor (34).  HNF4α is a 
nuclear receptor that regulates hepatic lipid metabolism and is implicated in diabetes and 
atherosclerosis (35). Nitronapthofuran compounds were found to directly bind to HNF4α 
activating transcription in HepG2C3A cells better than its natural ligand linoleic acid, leading to 
the development of newer routes for targeting these receptors in cells (36). Small molecule 
modulators have also been successfully employed to target protein homo/hetero-dimerization. 
Examples include small molecule modulators for c-Myc/Max, STAT3, p53 and Hap3p 
transcription factors (26,27,37-40). c-Myc is a bHLH protein involved in cell proliferation and 
differentiation suppression. Using high-throughput dimerization inhibitor assays, naphthols were 
identified as capable of disrupting c-Myc/Max interaction (40). Dichlorocarbazole 2 was also 
identified as capable of inhibiting c-Myc/Max in a yeast-hybrid library screen (41). STATs are 
TFs that dimerize via their phosphorylated SH2 domain and drive transcriptional responses that 
govern inflammation, apoptosis and immune response(42). Stattic disrupts STAT3 dimerization 
and translocation of STAT3 into the nucleus of HepG2 carcinoma cells rendering it very 
effective against STAT3 dependent cancer cell-lines (Figure 1.1)(39). p53 is a TF involved in 
cell-cycle control and in apoptosis pathways (43,44). P53 levels are tightly controlled by direct 
interaction with MDM2, a RING finger domain protein. MDM2 interaction with P53 could be 
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modulated by cis-imidazolines, benzodiazepine 11 and Nutlin3 (Figure 1.2) (37,38). All three of 
these p53 modulator compounds were also found to be active in cellular assays. Yeast HAP3 and 
its eukaryotic homologue NF-Y are known to bind as heterotrimers to consensus CCAAT DNA 
sequences to activate transcription. Using a novel high-throughput screening small molecule 
based micro-array dihydropyran 4 was successfully identified to bind to the yeast transcription 
factor Hap3 and its eukaryotic homologue NF-Y leading to a disruption in the formation of a 
Hap3 based hetero-trimeric complex(26).  
1.3.2 Targeting the DNA binding domain of transcription factors using small 
molecules 
Unlike the ligand binding domains of TFs, the TF DNA binding domains lack “druggable” 
pockets and are largely unstructured in the absence of DNA. Additionally, the DNA binding 
domain is highly positively charged and unlike the ligand binding domain of engages in 
numerous contacts with DNA (24,45). High-throughput screening approaches have resulted in 
the identification of small molecules that disrupt specific protein-DNA complexes, by direct 
interaction with the DNA binding domains as in the case of transcription factors like ER-α, B-zip 
proteins, AIF, NF-κB, HOXA13, HIF-1, STAT3 and HIVNCp7(39,46-52). Among DBDs, the 
zinc finger binding domains appear to be the best candidates for small molecule based inhibition 
of the DNA-binding activity. A platinated purine nucleobase compound was found to inhibit the 
HIV NCp7 zinc finger domains while the electrophilic disulfide benzamide and 
benzisothiazolone derivatives were found to be effective against the Estrogen receptor zinc 
fingers (Figure 1.2)(52,53). The small molecules that target these Zinc finger domains are 
usually electrophilic compounds that cause a Zn ejection from the DNA-binding domain 
resulting in a loss of the tertiary structure of the protein and subsequent abolishment the DNA 
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binding activity(52,53). The inhibition of the ERα zinc fingers by DIBA, an electrophilic 
compound gained much attention and provided a proof of principle for a new strategy to inhibit 
breast cancer at the DNA binding level, rather than the classical antagonism of estrogen 
binding(53). Recently, a high-throughput fluorescence anisotropy screen to identify inhibitors of 
the homeodomain protein Hoxa13 resulted in the discovery of a stereochemically complex 
lactam carboxamide that inhibited its DNA binding activity. The lactam carboxamide compound 
was prepared using diversity oriented synthesis and was also shown to be biologically active in 
Hoxa13 reporter assays(54). High-throughput fluorescence anisotropy assays have also been 
effective in identifying inhibitors of bZIP proteins and ERα (48). A high-throughput screening 
process aimed at identifying inhibitors that selectively bind to the DNA-binding interfaces of B-
zip transcription factors like CREB, C/EBPβ, VBP, and FOS|JUND was performed by Vinson C 
et.al., 2005 (48). The study identified inhibitors NSC13778 and NSC146443 that could inhibit all 
of the four B-zip transcription factors. Surprisingly NSC13778, was found to be able to 
discriminate between C/EBPβ and C/EBPα in selectivity assays (Figure 1.1) (48). Similarly, a 
high-throughput screen of over 11,690 compounds identified a small molecule theophylline that 
inhibited ERα from binding to its cognate DNA binding elements. ChIP and reporter assays 
further confirmed that theophylline is a powerful inhibitor of the DNA binding activity of ERα 
(47). Using a novel technique based on photonic crystal biosensors, researchers were able to 
identify aurin tricaryboxylic-acid as a low micromolar inhibitor of AIF, a non-specific chromatin 
binding protein(Figure 1.1)(49). Other examples include small molecules like galiellalactone and 
the platinum (IV) complex IS3 295 that directly block the DNA binding activity of STAT3 
(Figure 1.1)(55,56). NF-κB is a TF that plays a key role in immune system regulation in response 





Gallery of small molecule inhibitors of transcription factors namely Estrogen receptor 
alpha (Disulfide benzamide), STAT3 (Stattic, galliellalactone), AIF (Aurin tricarboxylic 
acid), HIF-1 (Echinomycin), p53 (Nutlin 3) and a bZIP protein inhibitor (NSC 13778) 







sesquiterpene lactones and dimeric procynaidins have been proposed to inhibit NF-ĸB DNA 
binding by direct interaction with the NF-ĸB DNA binding surface (51,57).Hypoxia inducible 
factor is a bHLH TF that is critical for responses to changes in oxygen level, especially hypoxia 
and plays an important role in vascular development and cancer tumors. Echinomycin is a DNA 
intercalator that is known to disrupt HIF-1 DNA binding to DNA through PAS domain (Figure 
1.1) (46,58). A comprehensive survey of the current literature reveals that the pharmacological 
potential of transcription factor DNA binding domains remains nascent and largely unexplored 
(21). Other than inhibitors of Zinc finger DNA binding domains, very few competitive inhibitors 
have been identified to target other structural classes of TF DNA binding domains.   
1.3.3 Alternative non-small molecule based strategies for targeting the DNA 
binding domain of transcription factors 
An alternative approach for targeting the DNA binding domains of transcription factors with a 
core inhibition strategy is by using DNA decoys or decoy-like aptamers. The aptamers utilize the 
natural propensity of transcription factors to bind nucleic acids and mimick the target sequence 
of the proteins thereby inhibiting transcription (59). Aptamers could either be single or double 
stranded RNA/DNA molecules although oligonucleotides with modified phosphorothioate DNA 
backbone are preferred as they are relatively resistant to nucleases within cells. Decoy aptamers 
have been used successfully to target a number of transcription factors like NF-ĸB, E2F, STAT-
3, c-Myc and Ets1 (60-64). A 14bp double stranded phosphorothioate aptamer Edifoligide, 
targeted against the cell-cycle transcription factor E2F, showed promise in initial clinical trials 
for treatment against smooth-muscle cell proliferation during surgical vein bypass but failed to 
show efficacy in Phase III trials(62). Similarly, a dsDNA decoy targeted against NF-κB DNA 
binding activity from Averina is in Phase I/II clinical trial for the treatment of eczema (65). 
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1.4 The Sox-HMG family of transcription factors as attractive targets 
for small molecule modulation 
The DNA binding activity of the Sox family of transcription factors is characterized by a ~80 
residue high mobility group (HMG) domain family that bind to a consensus 
C(T/A)TTG(T/A)(T/A) motif (66,67).  Its angular inner surface binds to the minor groove of the 
DNA and inserts a hydrophobic phenylalanine-methionine wedge into TT/AA DNA base pairs 
inducing a ~70º kink (Figure 1.2A) (68-71).It has been suggested that the induction of Sox 
specific kinks affects the gene regulatory outcome by initiating the assembly of specific 
regulatory complexes or enhanceosomes that crucially depends on the local shape of the 
DNA(72,73). The HMG domain consists of a three-helix bundle exhibiting an L-shaped structure 
composed of flexible major and minor wings that are subject to some structural rearrangements 
upon DNA binding (68,70,71,74). The functional and tissue specific gene expression programs 
of the Sox proteins are largely contingent on its differential partnership with other transcriptional 
regulators. Sox proteins are well known to physically interact with other transcription factors 
such as POU or Pax proteins contributing to the regulation of specific sets of genes involved in 
functions like eye lens development and stem cell pluripotency(70,75-79). Most of the HMG 
family members are key regulators of mammalian cell development patterning and are critical 
for cellular differentiation (79,80).  Structurally, the Sox-HMG family belongs to a larger group 
of HMG proteins that could be classified into the HMG nucleosome binding family (HMGN), 
the HMG AT-hook family (HMGA) and the HMG-box family (HMGB) (81,82).  Furthermore 
the HMGB family could be classified into the non-sequence specific and sequence-specific 
HMG families(82). The Sox-HMG family is a sequence specific HMG box and there are ≥ 20 









A) The HMG box of the Sox family of proteins is primarily a three-helix bundle that binds to 
the minor groove of the DNA inducing a ~70ºbending as observed in the case of Sox2 
(PDB:1GT0).  
 
B) An unrooted neighbor joining phylogenetic tree generated using MAFFT and visualized 
using splitstree showing the different groupings of representative human Sox-HMG 
domain sequences (1-3). 
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The online multiple sequence alignment program MAFFT and visualized using splitstree shows 
the different phylogenetic groupings (Groups A-H) of the Sox-HMG domains.  (Figure 1.2B) (1-
3).  The prototypical sox gene Sry, belongs to Group A, Group B1 consists of Sox 1, 2, 3, Group 
B2 consists of 14, 21, 25, Group C consists of Sox 4, 11, 12, 22, 24, Group D consists of Sox 5, 
6,13, 23, Group E consists of Sox 8, 9, 10, Group F consists of Sox 7, 17, 18, Group G consists 
of Sox 15, 16, 20, Group H consists of Sox 30, Group I consists of Sox 31 and finally Group J 
consists of Sox 32, and Sox33(1). 
1.4.1 Role of Sox family of proteins in stem-cell biology 
The Group B1 Sox HMG Sox2 is normally expressed in pluripotent mammalian cells and plays a 
key role in the maintenance of cellular pluripotency (67).  Sox2 is also required for self-renewal 
of embryonic stem (ES) cells (83). By featuring in a cocktail of four transcription factors 
required for generating induced pluripotent stem (iPS) cells Sox2 gained a lot prominence (84). 
Consistently, knockdown of Sox2 results in the loss of the undifferentiated state (85,86). Sox2 
directly interacts with different members of the Oct family of proteins when bound to its DNA 
targets like UTF1and Fgf4and engages in a number of gene expression programs pertaining to 
stem-cell pluripotency and cell development(87,88). Rational mutation of a Sox2 interface 
residue with Oct4 based on the Fgf4 crystal structure is known to perturb the ability of the 
interface-mutant Sox2 to form pluripotent stem cells (89). 
1.4.2 Role of Sox family of proteins in mammalian cellular development 
The Group A Sox HMG Sry is critical for testis development in mammals.  Ectopic expression 
of this gene is known to induce testis formation in XX transgenic mice while its deletion or 
mutation has been known to cause female genitalia in XY humans (90-93). The GroupB1 
member Sox2 is known to bind co-operatively with Pax6 to form a ternary complex on the DC5 
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enhancer eliciting eye lens placode formation while mutations in its Sox2-HMG domain have 
been associated with microphthalmia (77,94-97).  Mutations in Group B2 Sox14 gene have been 
associated with limb development defects like Mobius Syndrome while Sox21 knockout mice 
display hair loss and is hypothesized to be responsible for hair-loss condition in humans (98,99). 
The Group F member Sox7 is involved in parietal endoderm differentiation and is known to be 
critical for the induction of Gata4 and Gata6 (100).  Sox17 and Oct4 have been known to co-
express in endoderm cells and is presumed to cooperatively bind on a “compressed” Sox-Oct 
motif (80,89). Sox18 acts as a molecular switch to induce differentiation of lymphatic 
endothelial cells by activating Prox1 and  mutations in the Sox18 gene have been associated with 
lymphatic obstruction and vascular lesions (101,102).The Group G Sox-HMG member Sox15, 
plays a crucial role in skeletal muscle regeneration, while Sox9 is known to be critical for 
cartilage development. Mutations in the Sox9 gene have been known to cause campomelic 
dysplasia, a skeletal malformation syndrome (103,104).  
1.4.3 Role of Sox family of proteins in neural biology 
The Group B1 HMG Sox3 is known to be highly expressed in ventral diencephalon and 
mutations of Sox3 is known to have a significant effect on cognitive activities (105). Sox2 
interacts with Brn2 on a nestin enhancer element and this partnership is known to play a key role 
in brain development (106). Sox1 is known to have roles in post-mitosis controlling neuronal 
cell-specific differentiation of ventral striatum neurons (107,108). The Group B2 Sox HMG 
proteins Sox14 and Sox21 have been known to antagonize Group B1 Sox-HMG proteins (109). 
For example, Sox21 promotes neuronal cell differentiation by competing with the Group B1 
interaction partner like Pax6, while Group B1 proteins are known to be required for maintaining 
the undifferentiated state of neural cells (110,111). The Group C Sox-HMG representatives Sox4 
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and Sox11, are expressed in post mitotic neuro blasts resulting in activation of Tuj1 and MAP2 
markers for neuronal differentiation (112). The Group D members Sox5 and Sox6 are known to 
antagonize the SoxE family in oligodendrocyte development by competing with SoxE proteins 
for the same binding sites as is observed in competition between Sox5 and Sox10 to bind to 
myelin gene promoters (113-115). The Group E Sox-HMG members Sox8 and Sox10 are known 
to have important roles in oligodendrocyte differentiation and is also known to be essential for 
neural crest and peripheral nervous system development in (116) (117,118). 
1.4.4 Role of Sox family of proteins in Cancer 
Elevated expression levels of  the Group B1 Sox2 is known to have been associated with a large 
number of tumor types in vivo and it is hypothesized that the up regulation of Sox2 expression in 
carcinomas may have important pathological relevance (119,120).Sox2 has recently been 
implicated in the transcriptional regulation of the oncogene CCND1 in breast cancer (121).  In 
another study, it was found that patients with the milder monoclonal gammopathy whose 
immune system developed anti-Sox2 antibodies in the earlier stages, showed better prognosis 
than patients with a full fledged myeloma, who fail to develop spontaneous immunity to Sox2 
(122). Sox2 has also been recently identified as a potential target for therapy in malignant 
glioma(123).The oncogenic potential of Sox2 received further recognition after elevated 
expression levels were detected in several tumors such as squamous cell carcinomas, lung 
cancer, gastric carcinoma, malignant glioma and in breast cancer (119,121,124) . Overexpression 
of the Group C Sox members namely Sox4 has been reported in adenoid cystic carcinomas and 
in breast cancer cell lines while Sox11 overexpression has been reported in anaplastic 
oligodendroglioma (125,126). These observations of the oncogenic potential of Sox proteins 
lends support to the “Cancer-stem cell” hypothesis that states that adult stem cells give rise to 
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cancer cells and that aberrant upregulation of Sox proteins promotes self-renewal, de-
differentiation, proliferation and cell-survival reminiscent of their role in stem cell biology (127). 
1.5 Overall scope of the research project 
In the light of the importance of Sox-HMG proteins in stem cell, cancer and developmental 
biology, it can be envisaged that small molecule inhibitors of Sox-HMG proteins will have three 
areas of application: (i) as potential therapeutic agents against cancer (Figure 1.3A) (ii) as tools 
to direct differentiation for in vitro tissue engineering (Figure 1.3B) (iii) and as a useful chemical 
reverse-genetic tool to mimic mutational/developmental disorders. 
1.5.1 Sox-HMG inhibitors as potential therapeutic agents against Cancer 
Because of their special properties associated with self-renewal - some of the Sox transcription 
factors are also known to drive analogous gene expression programs in both pluripotent cells and 
tumor cells play oncogenic roles in the maintenance and propagation of germ cell tumors (128) 
(67,129). The current anti-tumour drugs in the market target metabolic pathways active in mature 
and differentiated cancer cells but not pathways unique to cancer stem cells. As a consequence 
while the differentiated and mature cancer cells are eliminated by the conventional anti-tumour 
drugs, the cancer stem cells may survive and self-renew leading to new tumours (127). Therefore 
it can be expected that inhibitors designed to target pathways unique to cancer stem-cells like the 
Sox-HMG mediated pathways could potentially hold the key to more effective cures in 
tumorigenesis (119).  
1.5.2 Sox-HMG inhibitors as tools to direct differentiation for in vitro tissue 
engineering  
Embryonic stem cells (ESCs) hold promise in the field of regenerative medicine and therefore 
targeting key transcription factors like the Sox-HMG family with small molecules  has the 
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potential to control stem cell fate and in directing differentiation processes for many practical 
applications towards stem-cell based therapies (130) (131,132). For example, Sox2 is a key-
factor responsible for the maintenance of the stem-cell like property of neural stem cells and 
there is a potential that Sox2 inhibitors either alone or in combination with other growth factors 
may be used to direct the neural stem cells in-vitro into special neural cell types like astrocytes or 
oligodendrocytes (86).  
1.5.3 Sox-HMG inhibitors as chemical reverse genetic tools 
Sox-HMG inhibitors will also serve as useful chemical reverse-genetic tools to mimic mutational 
disorders that affect the biochemical function of Sox proteins. For example, mutations in the 
Sox2-HMG domain that abolish DNA binding, have been associated with genetic disorders like 
Anophthalmia-Esophageal-Genital (AEG) syndrome (96). Thus, animal models can potentially 
be induced by Sox2-HMG inhibitors to mimic these genetic disorders in a cheap and reversible 
manner unlike RNAi based techniques or knock-out methods, which do not have stable dose 










A) Conventional chemotherapeutic agents target the somatic cells that form the bulk 
of the tumor but do not target the CSCs which would form a small fraction of the 
tumor mass causing a relapse of the tumor. By selectively targeting CSCs using 
novel drugs that target aberrant transcription factors involved in cancer stem cell 
formation, it would be possible to treat aggressive tumors. 
 
B) Sox2 expression universally marks embryonic and neural progenitor stem cells. A 
hypothetical Sox2 inhibitor either alone or in combination with other small 
molecules may have applications in directed differentiation of stem cells into 





1.6. Sox2 as a prototypical candidate for high throughput screening to 
identify inhibitors of the Sox-HMG domain 
Sox2 is a prototypical representative of the Sox-HMG domain family that binds to a consensus 
(A/T) (A/T) CAA (A/T) G core and is approximately 40% identical to the rest of the family 
members (67,111). The DNA binding interface of Sox2 is predominantly cationic, extended, 
with no binding pockets and bends DNA at an angle of ~70 degrees comparable to other Sox 
proteins like Sox4 and Sox17 (13,70,71). Sox2 is known to play a critical role in the maintenance 
of stem cell pluripotency and self-renewal of ES cells(67,83) . Since Sox2 is known to confer the 
property of “Stemness” it can be conceived that Sox2 inhibitors may be used to enable directed 
differentiation of stem-cells into mature phenotypes. Sox2 has also been reported to have 
oncogenic potential and therefore tumors with deregulated expression of Sox proteins might be 
treatable with small molecule inhibitors (Figure 1.3A) (119,124).Overall, the biological 
properties of Sox2 in stem cell and cancer biology makes it desirable for small molecule 
modulation and the identification of a potential inhibitor of Sox2-HMG by high-throughput 
screening methods could in principle be extended to target other Sox-HMG proteins. In this 
context, a brief introduction to high-throughput screening techniques and small molecule 
libraries will be provided below. 
1.7 High throughput screening techniques 
HTS assays can either be biochemical or cell based and come in many formats (24, 96, 384 or 
1536 wells). HTS can be either carried out on live cells to study certain processes like apoptosis 
or it can be a biochemical assay using purified proteins to target a specific protein (like a protein 
kinase) (133). Cell based HTS assays are usually reporter gene assays (luciferase, GFP), cell 
proliferation assays and secondary messenger assays (calcium ion, NADH concentration). Cell 
20 
 
based assays can also be high-content in nature (High-content screening) where live cells are 
analyzed for multiple parameters like multiple fluorescent reporters, phenotypical changes, 
cellular apoptosis, cytoskeletal rearrangements, nuclear DNA content etc., during small molecule 
screening. Unlike HTS which usually measures one or two parameters, high content screening 
yields more temporal, spatial information and generally analyses multiple parameters leading to 
more efficient primary hit optimization (133). Biochemical assays predominantly require volume 
miniaturization and involve read-out techniques like fluorescence, luminescence, radioactivity or 
UV absorption, depending on the scope and design of the assay. In particular luminescence based 
screens like the Alpha screen, scintillation proximity assays that make use of radioactivity and 
fluorescence based assays that utilize FRET, fluorescence anisotropy, fluorescence correlation 
spectroscopy, fluorescence intensity distribution analysis and time-resolved fluorescence are 
most popular as biochemical assays as fluorescence\luminescence based assays are typically 
sensitive even at low reagent concentrations and can be scaled up well for high throughput 
measurements (133). 
1.7.1 Small Molecule Libraries 
An important component of high-throughput screening is the choice and size of small molecule 
libraries. A number of small molecule libraries are commercially available that cover a wide 
range of pharmacological chemical space. The pharmacophore chemical space essentially refers 
to descriptors like hydrogen bond acceptor, hydrogen bond donor, hydrophobic, charged and 
aromatic groups that could be used to theoretically classify compounds(134). Compounds with 
very different structures might also have similar chemical descriptors and hence libraries can be 
constructed to cover different subsets of pharmacophore space (134). Some of the most 
recognized chemical library providers are the Chembridge corporation, Chemdiv Inc., the 
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Maybridge screen, the Natural products libraries from MerLion and the NCI repository of small 
molecule libraries.  
1.7.1.1 The Chembridge libraries (http://www.chembridge.com) 
The library has more than 500,000 compounds in its repositories although screeners typically 
prefer more mid-sized libraries like the ChemBridge DIVERSet, which have about 50,000 
compounds that cover about 60-65% of the entire chembridge pharmacophore space. 
ChemBridge also offers investigators to pick smaller subsets of 5,000-10,000 compounds from 
the DIVERSet depending on the requirements of the biological target for screening. 
1.7.1.2 The Chemdiv libraries (http://www.chemdiv.com) 
The ChemDiv library is one of the largest libraries with a collection of over million compounds 
with about ten percent of the total collection dedicated to specific targets like kinase inhibitors, 
GPCRs, ion-channels and developmental pathway modulators. Overall, the ChemDiv library is 
represented by approximately 10,000 uniquely diverse scaffolds with as much as 700 compounds 
per scaffold population having greater than 90% purity by NMR. 
1.7.1.3 MayBridge screen (http://www.maybridge.com) 
The MayBridge collection of 60,000 compounds covers ~87% of the 400,000 pharmacophores 
defined by the world drug index and are known to obey Lipink´s “rule of five” thereby generally 
demonstrating good absorption, distribution, metabolism and excretion profiles. MayBridge also 
offers a reduced version known as the preplated HitFinder with a collection of 16,000 
compounds selected to represent the diversity of their 60,000 compound collection. 
1.7.1.4 The Natural Products library from MerLion (http://www.merlionpharma.com) 
The Singapore based MerLion Pharmaceuticals is known for its collection of about 1,800 
purified natural compounds from Fungi, Plants and Actinomycetes, out of which about 300 
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compounds are completely new structures that are not available in any other natural products 
library. The MerLion natural products collection consists of compounds of the class like tannins, 
terpenes, steroids, alkaloids, polyketides, aminoacids, aromatics, carbohydrates, glycosides, 
flavonoids, peptides and polypyrroles.   
1.7.1.5 NCI Chemical libraries (http://dtp.nci.nih.gov) 
The NCI DTP repositories houses a uniquely diverse set of about 200,000 compounds, that are 
shipped annually to research investigators around the world free of cost except for shipping 
charges. The NCI also makes available four reduced set of libraries from their entire collection 
using different selection processes resulting in what is known as the approved oncology drugs set 
(97 compounds), the challenge diversity set II (1364  compounds), the mechanistic set (879 
compounds) and the natural products set (120 compounds).  
A survey of more than 2.6 million compounds from over 32 different chemical providers 
including the ChemBridge, ChemDiv, MayBridge and the NCI chemical libraries were carried 
out for assessing properties like drug-likeness, lead-likeness, fingerprint based diversity and 
frameworks (134). The assessment revealed that the NCI database is the top most representative 
of the diversity in chemical space covering about 59% of the chemical space of the whole 
database of 2.6 million compounds. Even in selection processes that rank for “lead-like” drugs, 
the NCI compound collection emerged as the top-most diverse database among all of the 32 
chemical providers (134). The NCI library collection also have the additional incentive that these 
libraries could be procured free of cost. 
Hence the reduced NCI library sets namely the NCI Challenge diversity set II and the NCI 
Mechanistic diversity set were chosen for ideally beginning the campaign screen. The NCI 
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libraries were also chosen to make an initial assessment of the success in terms of the number of 
“primary” hits that could be obtained given the chemical diversity of the library collection. 
1.7.1.5.1 NCI Challenge diversity set II 
The challenge diversity set consists of 1364 compounds derived from almost 200,000 
compounds available with the DTP repository. The pharmacophoric space of these 200,000 
compounds was reduced using the ChemX (Oxford Molecular group) and Catalyst (Accelrys 
Inc.,) programs creating a diverse set of compounds that were amenable for structure-based 
hypotheses. The final set consisted of 1364 compounds that are more than 90% pure and consists 
of molecules that are relatively rigid, planar, having atmost one chiral centre and does not 
contain undesirable pharmacophore groups like organometallics, polycyclic aromatic 
hydrocarbons and weakly bonded heteroatoms. 
1.7.1.5.2 NCI Mechanistic diversity set 
The mechanistic diversity set consists of 825 compounds derived from 37,836 open compounds 
known to have activity in NCI human tumor 60 cell line screens. In contrast to the structural 
diversity of the compounds that constitute the challenge library, the mechanistic diversity 
consists of compounds known to have a diverse growth inhibition pattern (broad GI50 range) on 
the human tumor 60 cell line screen. Compounds that exhibited activity in the human tumor 60 
cell line were clustered using FASTCLUS resulting in 1272 clusters. 825 representative 
compounds for which sufficient material was available was chosen from each one the 1272 





1.7.2 The role of academic high-throughput screening in addressing 
unconventional biological targets 
The concept of high-throughput screening, once solely the forte of major pharmaceutical 
companies is increasingly becoming amenable for academic researchers and research institutes 
and this has lead to a greater variety of targets being screened than would be in the 
pharmaceutical industry(135). Unlike pharmaceutical companies where the budgets, equipment 
and manpower are largely focused on targets that would fetch a billion dollar drug, academic 
high-throughput screening even with its limited resources is ushering in a slow and silent 
revolution, as the financial and research priorities are different (136). A number of broad 
research problems that addresses rare genetic diseases, basic cell physiology, difficult protein 
targets etc., can all be tackled with more freedom in an academic high-throughput screening 
setting. Academic screening unlike industrial screening has also resulted in an open source 
environment of sharing the results of high-throughput screening through academic publications 
or through databases like PubChem(137). Integration of small molecule structures with genomic, 
proteomic, crystallographic and high-throughput screening information in public databases like 
PubChem has enabled the academic community to identify criteria for selecting lead compounds 
with potential for further development.  
In this context, it must be mentioned than an academically interesting class of inhibitors that 
arose from high throughput screening in the current study is the inorganic polyoxometalates.  A 
wells Dawson polyoxometalate was identified as a primary hit in the high-throughput screening 
for inhibitors of Sox-HMG DNA binding domain in this study. Hence, the chemistry and 
biological properties of polyoxometalates will be examined in detail below as this class of 
molecule is central to the current study.  
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1.8 The chemistry of polyoxometalates 
Polyoxometalates are inorganic compounds built on a framework of oxyanions derived from 
transition metals belonging to Group 5 and 6 of the periodic table in their highest oxidation states 
(138). Examples of transition elements that form polyoxometalates are Vanadium, Molybdenum 
and Tungsten (138). The oxyanions are held together by oxygen atoms and enclose one or more 
central heteroatoms like phosphorus or silicon.  Typically, polyoxometalates are nanometer sized 
aggregates, with a high negative charge density and a versatile structural architecture that is 
amenable to modification with organic functional groups. Polyoxometalates are synthesized from 
a condensation reaction of oxyanions in an acidified solution, resulting in the formation of a 
framework of oxyanion bridges that get repeated in a regular manner (5,139). The condensation 
reaction can be controlled by the choice of solvent used, pH, temperature, stoichiometry and 
counterions resulting in a number of different polyoxometalate structures. 
For example, the Dawson polyoxometalate K6[P2M18O62] can be synthesized by a condensation 
reaction of sodium molybdate in a phosphoric acid and potassium chloride solution (5).  
Na2MoO4.2H2O +      H3PO4 +    HCl +    KCl   →   K6[P2Mo18O62].12H2O 
(Sodium Molybdate)  (Phosphoric acid)                 (Dawson potassium phospho-molybdate) 
Polyoxometalates find a number of applications in the field of nuclear waste treatment, (electro) 
catalysis, nanotechnology, material sciences and in medicine. Some common (though not limited 
to) structural polyoxometalate families of importance in the field of biomedicine are the 1) 
Keggin structure [PM12O40]n-, 2) the wells-Dawson structure [P2M18O62]n- 3) the preyssler 
structure [MP5W30O110]n-and 4) the lindqvist structure [M6O19]n–where “M” is the transition 
metal atom and “n” is the number of ionic charges (Figure 1.4) (138). Many of the physical 
properties of polyoxometalates like redox potential, aciditiy, elemental composition, structure, 
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charge density and distribution is amenable to varying degrees of alteration making it attractive 
for biomedical applications. Since much of the current study, places a great emphasis on the 
Dawson polyoxometalates[P2M18O62] n- and the Keggin polyoxometalates[PM12O40]n-their 
structural aspects will be examined in detail below. 
1.8.1 General structure of the Dawson-Polyoxometalate [P2M18O62]n- 
The Dawson Polyoxometalate is a prolate ellipsoid consisting of two cap centers, each made of 
three molybdenum or tungsten atoms forming a triad and two equatorial belt centers of six 
molybdenum or tungsten atoms each  (Figure 1.4 A). Two internal caged phosphates co-ordinate 
the cap and belt centers. In total, there are 18 terminal and 44 bridging (36 two-, 6 three-, and 2- 
four coordinated) oxygens. Three isomeric rotational forms of the metal-oxygen unit are known 
to exist for the Dawson polyoxometalate namely α, β and γ. 
1.8.2 General structure of the Keggin-Polyoxometalate [PM12O40]n- 
The Keggin polyoxometalate is spherical in shape and has a central tetrahderal phosphate 
arranged as units of four M3O13 units, giving it a global tetrahedral structure (Figure 1.4 B). Each 
of the four M3O13 units can be found in two possible orientations in the caged framework thus 
making five rotational isomeric forms possible namely α, β, γ, δ and ε. The Dawson structure can 








Ball and stick representation of some fundamental polyoxometalate structures namely 
 
A) Dawson [P2M18O62] n– 
B) Keggin [PM12O40] n– 
C) Preyssler[MP5W30O110] n– 
D) Lindqvist[M6O19]n– 
 
where “M” is the transition metal atom and “n” is the number of ionic-charges. Small 
light gray spheres are oxygen atoms and the bigger dark spheres are transition metals like 










1.8.3 The stability of polyoxometalates (POMs) 
POMs generally undergo multiple condensation-hydrolysis equilibria in solution depending on 
the pH and temperature(140). Hence one of the critical issues in all biological studies is to 
evaluate the stability of the POM under consideration. A number of studies have highlighted the 
difficulty and challenge involved in identifying the final active POM species in aqueous 
solutions and biological media (141,142). In the absence of NMR, kinetic or thermodynamic 
speciation data, a number of studies on POMs have been limited in their identification of the 
active hydrolytic species (139,141). For example, the classic phospho-molybdic Dawson-type 
POMs like (NH4)6P2Mo18O62.12H20 decompose into the lacunar Keggin-type anion 
HxPMo11O39(7-x)-,pentamolybdodiposphate HxMo5P2O23(6-x)-, phosphate and oxomolybdate 
regardless of the pH of the solution(140). A more detailed profile of the hydrolysis reaction of 
the Dawson-POM is shown below. 
Decomposition reaction of the Dawson-anion: 
2P2Mo18O626- + 3H2O ->     2HxPMo12O40(3-x)-      +       HxP2Mo5O23(6-x)-        +   Mo7O246- 
(Dawson)                             (Keggin-type)      (pentamolybdodiphophate)   (heptamolybdate) 
If pH ≥ 6.0 then heptamolybdate breaks down to molybdate species 
Mo7O246-      +    4H2O    ->    7MoO42- +     8H+ 
(heptamolybdate)                      (molybdate) 
If pH ≥ 2.0 then Keggin-type breaks down to lacunar Keggin-type species 
PMo12O403- +    3H2O ->     PMo11O397-            +     MoO42-+      6H+ or 




If pH is 0≤pH ≤ 2.0 then Keggin-type anion precipitates into ammonium phospho-molybdic 
salt 
HxPMo12O40(3- x)-  + 3NH4+          ->     (NH4)3PMo12O40.4H2O                                  +       xH+  
(Keggin-type)                                 ammonium phospho-molybdic salt 
If pH ≥ 6.0 then pentamolybdodiphophate hydrolyses to molybdate and phosphate species 
P2Mo5O236-                             +     5H2O ->     5MoO42-    +    2HPO42- + 8H+ 
(pentamolybdodiphophate)                   (Molybdate)    (Phosphate)  
1.8.4 Functionalization of Dawson polyoxometalates 
Organic derivatization of polyoxometalates, by modulation of properties like stability, 
bioavailability, toxcitiy and specific receptor recognition has a number of significant applications 
in biomedicine (139,143). A number of derivatized Dawson polyoxometalates were used in the 
current study and hence functionalization of this particular class of polyoxometalates will be 
elaborated in detail in this section. Bareytet.al. 2005, described a general method for organic 
derivatization of Dawson polyoxometalates, wherein the polyanion α-[P2W18O62]6- in a buffered 
solution of Tris and Lithium tungstate can be used to remove an equatorial metal-oxygen unit to 
give rise the lacunary Dawson α1-[P2W17O61]10-. The α1 isomer α1-[P2W17O61{SnR}]7-, could be 
obtained by suspending the lacunary Dawson POM α1-[P2W17O61]10-  in a trichlorostannane 
Cl3SnR solution with TBABr (tetra-butyl ammonium bromide) in acetonitrile (Figure 1.5 A) 
(144). Likewise, treatment of α-[P2W18O62]6- with a mild base like bicarbonate results in the 
removal of a terminal metal-oxygen unit giving rise to lacunary Dawson POM α2-[P2W17O61]10-. 
Such an isomeric lacunary Dawson can have a variety of metal-atoms incorporated into its 











A) Treatment of α-[P2W18O62]6- in a buffered solution of Tris and Lithium tungstate 
results in lacunary α1-[P2W17O61]10- which upon  treatment with a 
trichlorostannane Cl3SnR yields the polyanion of the form  α1-[P2W17O61{SnR}]7- 
that can be precipitated by TBABr. 
 
B) Treatment of α-[P2W18O62]6- in a buffered solution of bicarbonate results in 
lacunary α2-[P2W17O61]10- which upon  treatment with a trichlorostannane Cl3SnR 

































polyanion of the form α2-[P2W17O61{SnR}]7- that can be precipitated by TBABr (Figure 1.5 B)  
(144). The tin atom is coordinated by being bound to one of the central phosphate groups, with  
the overall Dawson polyoxometalate structure acting as a pentadentate ligand. The sixth position 
of the tin atom is typically attached to organic moieties and open for further derivatization. 
Compared to the α2 isomer, the α1 isomer is chiral and therefore has a great potential in 
biological applications. The tin substituted α1 and α2 wells Dawson polyoxometalates thus have 
a flexible chemistry enabling amines, peptides and alcohols to be attached to the side chains with 
promising prospects in the field of biomedicine (144). In recent times, click chemistry based 
methods (copper-catalyzed azide/alkyne cycloaddition) have further expanded the range of 
organic substrates that could be attached to the polyoxometalate framework(145). 
1.8.5 Biological activities of polyoxometalates 
1.8.5.1 Anti-viral activities of polyoxometalates 
A number of invitro studies on POMs revealed that they are effective against a broad spectrum of 
viruses like the Rhabdovirus, HIV, Rabies, polioviruses and Murine Leukemia sarcoma (MLSV) 
(146,147). One of the most notable anti-viral POMs was the tungstoantimonate HPA-23 that was 
under study for the treatment of HIV(148). However, clinical trials of HPA-23 revealed toxicity 
and low anti-viral activity rendering the drug unacceptable(149). Since then a number of efforts 
have been made to chemically render POMs benign and to reduce their toxicity  (139). Large 
scale systematic studies on POMs have revealed that the anti-viral activity of polyoxometalates 
is dependent not only on the structural class, charge, composition, counter-ion and size of the 
POM but also on the cell-line and virus under observation(138). A number of polyoxometalates 
tested invivo on mouse models infected with Scrapie virus, Human Simian Virus and Flavivirus 
infections have also shown encouraging results upon polyoxometalate treatment(138).  
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1.8.5.2 Anti-tumor activities of polyoxometalates 
One of the earliest studies on the anti-tumor activity of polyoxometalates was an invivo study of 
human patients with carcinoma of the intestinal tract. A combination of phosphotungstic acid, 
phospho-molybdic acid and caffeine was used on patients and after 2-4 weeks the cancerous 
growth was observed to have been ameliorated (150). Mice implanted with subcutaneous tumor 
were found to have a substantial reduction in tumor volume after injection with Anderson-type 
polyoxomolybdates and  heptamolybdates (138). The mechanism behind the anti-tumoral 
activity of heptamolybdates is proposed to be derived from the toxicity of the reduced form of 
the heptamolybdate [Mo7O23(OH)]6- as compared to its oxidized state[Mo7O24]6-. The [Mo7O24]6 
reduction to [Mo7O23(OH)]6- is brought about by charge transfer from oxygen-to-molybdenum by 
flavinmononucleotide, a natural reductant in tumor cells (138). A number of studies of 
derivatized polyoxotungstates against different cancer cell-line invitro have been able to 
correlate cytotoxicity with reduction potential, the size and composition of the POMs (151). 
Starch-encapsulated POMs have also been found to be very effective in enhancing the anti-tumor 
effect of [CoW11TiO40]8– in mice, albeit with much lower toxicity as compared to drugs like 
cyclophosphamide and fluouracil (138,152).  
1.8.5.3 Polyoxometalates as competitive inhibitors of the DNA binding activity of 
HIV-1 RT and Rad 51 
One of the earliest studies of the effect of POM on HIV-1 RT showed that the POM 
[(O3POPO3)4W12O36]16- acts as a competitive inhibitor of RT DNA binding, due to a strong 
POM-polycationic enzyme interface interaction  (153,154). The anti-nucleic acid binding activity 
of polyoxometalates was demonstrated in another example where sodium-metatungstate was 
reported to act as a competitive inhibitor of the archaeal protein Rad51(155). A crystal structure 
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was reported by Luo et.al in 2009 that had serendipitously captured Rad51 bound to sodium-
metatungstate, an ingredient used in the crystallization condition of Rad51(155). The structure 
revealed that the POM bound to the negatively charged DNA binding surface of Rad51, 
explaining its competitive DNA binding inhibitory activity.  
1.8.5.4 Polyoxometalates as non-competitive inhibitors of CK2 and Kinesin 
 CK2 is a protein kinase critical for cell proliferation and survival and is known to become 
overactive in a number of cancers like prostate cancer and acute myeloid leukemia(156,157).The 
Dawson polyoxometalate K6[P2Mo18O62] was found to be a nano-molar, non-competetive 
inhibitor of CK2 with a relatively high degree of selectivity over 29 other serine/threonine and 
tyrosine kinases (141). Kinesins are proteins that interact with microtubules and are essential for 
the formation of bipolar mitotic spindle (158). Small molecule inhibitors of Kinesins have 
immense applications as anti-cancer agents. The Dawson polyoxometalate K6[P2Mo18O62] was 
also shown to inhibit kinesin-5, disrupting its binding to microtubules (159). This inhibitory 
activity was observed to be non-competetive with monastrol binding to kinesin-5.  
1.8.5.5 Polyoxometalates as inhibitors of HIV-1 protease, Neuraminidase and 
HDACs 
Studies on HIV-1 protease revealed that the wells-Dawson polyoxometalate 
K7[P2W17(NbO2)O61] inhibits HIV-1 protease with an IC50 of 2.0 μM (154). Based on molecular 
modeling, two different binding regions for the POM were proposed on the HIV-1 protease. The 
positively charged “hinge” region of the HIV-1 flaps was proposed to be the most probable 
binding site for POM with the active site in its “flaps-open form” being the second most 
proabable binding site (154,160).  In another study on RNA viral proteins, titanium containing 
polyoxotungstates were found to exhibit strong anti-influenza activity (161). Molecular modeling 
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and dynamic studies later revealed that the POMs exhibit a very strong electrostatic interaction 
with the viral protein Neuraminidase, highlighting its potential as a promising candidate against 
the ever increasing mutant forms of influenza Neuraminidase (162).  Most recently a 
polyoxometalate PAC-320, a tri-organic-tin-substitute germanotungstate was found to be a very 
strong inhibitor of HDAC intra-cellular activity in cancer cell lines (163). 
1.8.6 Delivery of polyoxometalates inside cells 
As polyoxometalates are large and highly negatively charged their penetration of cellular 
membranes poses a serious challenge. Surprisingly, a number of studies have revealed that 
POMs do cross the semi-permeable membrane as in the instance where using raman 
spectroscopy and photonic microscopy, HPA-23 was found to penetrate through C3HBi 
fibroblast cells (139,164). Polyoxometalates loaded into starch  nanoparticles were tested in mice 
and this encapsulation was found to extend its stability, anti-tumoral activity and survival rate 
(165). Liposome encapsulation (LEP) of POMs K6SiW11TiO40 {(SiW11Ti) LEP} was found to 
help retain the parent structure of the POMs resulting in enhanced stability, anti-tumoral activity, 










1.9 Aims of the research project 
The specific objectives of this research project are 
1. To show that a prototypical Sox-HMG TF DNA binding domain is chemically tractable 
and therefore expand the boundaries of TF drug targeting. Demonstrating chemical 
tractability of a TF DNA binding interface can be expected to falsify the underlying 
presumption that transcription factor-DNA interactions are chemically “undruggable”. 
2.  The project will utilize structurally and mechanistically diverse chemical libraries in a 
high-throughput screening approach using fluorescence anisotropy to identify small 
molecule inhibitors that interfere with Sox2-HMG –DNA interaction under equilibrium 
conditions. More precisely, the small molecule would inhibit the binding of Sox2 to the 
CCND1 (an oncogene) regulatory DNA element that was identified to be occupied by 
Sox2 in both hES cells and breast cancer cells (67,129). 
3. The mechanism of interaction of the inhibitory candidate small molecule with Sox2 will 
be deciphered through biophysical and structural biology studies. 
4. Whenever deemed appropriate, sufficient chemical modifications of the candidate hit 
molecule would be made and its selectivity would be assessed with a panel of Sox-HMG 

















METHODS AND MATERIALS 
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2.1 Protein expression and purification 
2.1.1Sox2-HMG domain expression and purification  
The HMG domain of Sox2, spanning residues 33-141 (Sox2HMG) of the full length mouse 
protein was cloned into pETG20A expression vector (166). A single colony of chemically 
competent BL21(DE3) E.coli cells transformed with the expression plasmid was initially 
cultured overnight in 100ml Luria Bertani (LB) containing 100ug/ml ampicillin at 37ºC shaken 
at 220 r.p.m. The following day, 10ml of culture was added to 1 liter of LB containing ampicillin 
and incubated with shaking at 37ºC until the OD 600 was ~0.5 Protein expression was induced by 
addition of IPTG (Invitrogen) to a final concentration of 0.5mM. After a 4 hour shaking 
incubation at 30ºC, cells were harvested by centrifugation at 10,000 r.p.m for 5min (sorvall SLA 
3000). Cells were resuspended in Buffer C (50mM Tris-HCl, pH 8.0, 150mM NaCl), lysed by 
sonication and the lysate was clarified by centrifugation at 20,000 rpm for one hour (Sorvall 
SS34). The supernatant was purified by metal affinity using Ni-NTA (Qiagen) resin equilibrated 
with Buffer C. Protein was eluted in Buffer C containing 300mM imidazole. Eluted His6thrx-
Sox2-HMGprotein was desalted with Buffer A (50mM Tris-HCl pH 8, 100mM NaCl) on a PD-
10 desalting column in order to remove imidazole prior to Tobacco Etched Virus (TEV) protease 
digestion. The histidine-thioredoxin tag was removed by TEV digestion (substrate-to-enzyme 
ratio of 100:1) at 4ºC for approximately 16 hours. Sox2-HMG was purified by cation-exchange 
chromatography (Resource S column equilibrated with Buffer A) in order to remove the his6thrx 
tag and TEV from the digestion mixture. Sox2-HMG was eluted using a linear gradient ranging 
from 100mM NaCl to 1.0 M NaCl in Buffer A. Sox2-HMG was subjected to a final purification 
step using HiPrep Superdex-200 gel filtration column in Buffer A. Fractions containing Sox2-
HMG were pooled and concentrated to ~10mg/ml. The purity of the collected fraction was 
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verified in a SDSPAGE gel. 13C, 15N isotope labeled Sox2HMG was obtained by growing 
Escherichia coli cells in an overnight M9 minimal media containing isotope labeled glucose and 
ammonium chloride (Cambridge Isotope Laboratories) at 18ºC. One litre of the M9 minimal 
medium contained 52.7ml 1M Na2HPo4, 26.5ml 1M KH2Po4, 2ml 5M NaCl, 1.2ml 2mM 
MgSo4,1.2ml 0.1mM CaCl2,1.2ml 0.5%(w/v) thiamine-HCl, 2g 13C glucose (Cambridge Isotope 
Laboratories), 1g 15N ammonium chloride. Isotope-labeled Sox2-HMGwas expressed and 
purified using the same chromatographic procedures as described for unlabeled Sox2-
HMG(71).Appendix A shows the protein sequences and appendix B images of the purified Sox2-
HMG protein 
2.1.2 Sox-Homologs, REST C2H2, FoxA1 and AP2 purification 
The mouse REST C2H2 zinc finger protein was produced as described (167).  The mouse Sox 
paralogs Sox4, 5, 6, 7, 8, 9, 10, 11, 17 and Sox18 were kind gifts from Calista Keow Leng Ng 
and were purified using established protocols(168). Full length Ap2 was a kind gift from Tan Si 
kee and was purified using unpublished protocols. Full length FoxA1 was a kind gift from Hong 
Shuzen and was purified using unpublished protocols. Protein sequences are listed in appendix 
A. 
2.1.3 Pax6 paired domain expression and purification  
The mouse Pax6 paired domain spanning residues 4-136 (GI:220938183) was cloned into a 
pETG40A expression vector and expressed as a MBP fusion protein in BL21(DE3) cells at 18ºC 
by addition of 0.5mM IPTG in LB (Luria Bertani) media. Cells were collected by centrifugation, 
resuspended in a lysis buffer containing 40mM HEPES pH 7.5, 200mM NaCl, 5mM β-
mercaptoethanol and 2mM EDTA and sonicated on ice.  Fusion proteins were extracted from 
cell lysates using an amylose column (New England Biolabs) equilibrated with the lysis buffer 
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and eluted with the same buffer supplemented with 10mM maltose. The fusion MBP tag was 
cleaved using TEV protease at 4ºC for approximately 16 hours. A further purification by heparin 
column (GE) chromatography was performed to remove the MBP tag. Pax6 4-136 was eluted 
using a linear gradient ranging from 100mM NaCl to 1.0M NaCl and the purity of the proteins 
were found to be greater than 90%.Please refer appendix A for the protein sequences and 
appendix B for images of the purified Pax6 protein. 
2.2 Annealing DNA duplexes 
PAGE purified, labeled/unlabeled DNA elements were obtained from Sigma-Proligo. The DNA 
strands were annealed in an annealing buffer with a working composition of 20 mM Tris pH 8.0, 
50 mM KCl and 50 mM MgCl2 in a PCR thermocycler by initially ramping to a temperature of 
95ºC for 5 mins followed by a slow cooling to 4ºC at the rate of (0.5ºC/sec) .The sequences of all 
the DNA elements used in the study are provided in appendix C. 
2.3 Fluorescence anisotropy measurements 
The fluorescence anisotropy assay is a spectroscopic technique that measures the tumbling rate 
of a sample containing a fluorophore (169). A 22bp fluorescently labeled (Fluorescein) DNA 
element based on a cis-regulatory element of the CCND1 gene that has been reported to bind to 
Sox2 was chosen as the DNA substrate (See Appendix C for CCND1 sequence)(129). When 
polarized light excites the (FAM)-CCND1 element (5’ Fluorescein labeled cis-regulatory 
CCND1DNA element), the relatively small (FAM)-CCND1 element which undergoes rotational 
diffusion causes depolarization of the emitted light resulting in a low anisotropy measurement. 
When Sox2-HMG binds to (FAM)-CCND1, the larger size of the protein-DNA complex causes a 
slower rotation, resulting in a relatively higher polarization/anisotropy of the emitted light 








The principle of the fluorescence anisotropy based screening is that the fluorescently 
labeled DNA emits mostly depolarized light owing to its lower molecular weight as 
compared to the protein-DNA complex that emits partially polarized light because of its 
higher molecular weight. In a small molecule screening set-up, the difference in the 
intensity of polarized light can be measured to determine the bound and unbound states of 








assay, to identify small molecule inhibitors that can specifically disrupt Sox2-HMGDNA 
complexes. Assays involving fluorescein labeled DNA and Sox2-HMG were carried out in a 
black 384microplate (Corning NBS). The fluorescence anisotropy measurements from the 
microplates are read on a Spectramax M5 microplate reader (Molecular Devices) with excitation 
at 485 nm, emission at 525 nm and a cut-off filter of 515 nm. The PMT was set to a high 
sensitivity with number of reads per well set to 100.The buffer solutions for the fluorescence 
binding experiments (fluorescence anisotropy) had the final working composition of 10mM Tris 
pH 8.0 and 100mM KCl prepared with molecular grade water.  
2.3.1 High-throughput fluorescence anisotropy screening using the Sciclone 
ALH-3000 workstation 
All the liquid transfer steps involving assay reagents like protein, DNA and small molecules, to 
the 96 or the 384 well microplates, were automated using the Caliper Life Sciences, Inc.’s 
Sciclone ALH 3000 LiquidHandler Workstation. Two small molecule libraries, namely the 
Mechanistic (825 compounds, 1mM in 100% DMSO) and Challenge diversity library (1364 
compounds, 10mM in 100% DMSO) were procured from DTP, NIH 
(http://dtp.nci.nih.gov/branches/dscb/repo_open.html). Prior to screening, a working stock of 
both the libraries was created in 96 well microplates such that the final concentration of the small  
molecule was 20μM in 100% DMSO.  Since the chemical libraries employed for screening is 
dissolved in DMSO, different concentrations of DMSO was used to assess the tolerance of the 
assay. Increasing the DMSO concentrations seemed to lower the anisotropy of the bound Sox2-
DNA complex (Appendix D). However even at 12.5% DMSO, the assay retained a good signal 
window of ~85mA, suggesting that the assay is tolerant even at high DMSO concentrations 
(Appendix D). A schematic of the HTP screening setup is presented (Figure 2.2). Initially, 20.5ul 
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of Sox2-HMG was dispensed into 384 well Corning NBS microplates, followed by addition of 4 
μl of the small molecule from the working library stock. The small-molecule protein mixture in 
the microplate was incubated for one hour at 25°C. This initial step involving the addition and 
incubation of small molecules with the Sox2-HMG domain was to ensure that the candidate 
small molecule inhibitors get sufficient access to the DNA binding interface of Sox2. Addition of 
unlabeled DNA (4ul of 1uM CCND1DNA element) serves as the positive control for complete 
inhibition of Sox2- fluorescein labeled DNA complex while addition of DMSO (4μl of 100% 
DMSO) acts as the negative control. Finally, 20.5 µl of (FAM)-CCND1DNA (22bp duplex) 
containing a consensus Sox motif was then added to the 384 well microplate such that the total 
reaction volume in the microplate was 45μl. The assay reagents in the microplate were incubated 
for one hour at 25ºC after which the fluorescence anisotropy was recorded. The final reaction 
mixture in the microplate contained 75nM of Sox2-HMG, 1.77uM of small molecule and 1nM 
(FAM)-CCND1DNA.Screening of each small molecule library was carried out in technical 
duplicates with the screens being carried out on different days and on freshly prepared working 

















Overview of the fluorescence anisotropy based high-throughput screening for inhibitors of Sox2-








2.3.2 HTP fluorescence anisotropy screening data analysis 
The Z’ factor is a dimensionless parameter routinely employed in high-throughput screening to 
determine the signal window and precision for accurate assay performance evaluation(170). The 
Z’ factor for the HTP screening was calculated as  
 
𝑍𝑍′ =  1 −  [3 ∗ 𝑆𝑆𝑆𝑆(′ + ′  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) + 3 ∗ 𝑆𝑆𝑆𝑆(′−′  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)][𝑚𝑚𝑚𝑚(′−′  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐) −𝑚𝑚𝑚𝑚(′ + ′ 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)]  
--Eqn(1) 
SD (‘+’ control), SD (‘-‘control) are the standard deviations (SD) of the positive and negative 
control anisotropies during the screening while mA(‘-‘ control) and mA(‘+’ control) are the 
millianisotropy units (mA) of the positive and negative controls(170). A dimensionless Z-score 
measurement was used as the basis for internal-plate normalization. The Z-score values were 
calculated by subtracting the raw anisotropy value for each compound from the mean of all the 
measurements within the plate (including the positive and negative controls) and by subsequent 








iΧ  - is the raw anisotropy measurement for the ‘i’
th compound 
Χ  - is the mean of all anisotropy measurements in the plate 
xSD - is the standard deviation of all measurements in that plate 
Thus, each small molecule receives an algebraically assigned “+” or “-“ Z-score depending on 
the number of standard deviations the anisotropy value fell above or below the mean of each 
microplate. Compounds that tend to lower the anisotropy of the completely bound Sox2-
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DNAcomplex have negative Z-scores, while those that increase the anisotropy of the complex 
have positive Z-scores. As the screening experiments were carried out in duplicates, the replicate 
Z-scores for each compound were combined to produce a Composite Z-score. The composite Z-
score was calculated as a vector projection of each Z-score in duplicate onto an imaginary <1, 1> 
line of perfect reproducibility(171).  
The amplitude of the projection of the measurement vector of the technical replicates (Z-score 
screen1, Z-score screen2) onto <1, 1> is given as 
 
𝐶𝐶𝑐𝑐𝑚𝑚𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶 𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 =  𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝑆𝑆𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐1 + 𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝑆𝑆𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐2
√2  
--Eqn(3) 
Reproducibility value for each compound was calculated as the cosine of the angle between each 
Z-score and the imaginary<1,1> vector(171). The reproducibility values therefore range from –1 
to +1.The reproducibility values for each compound were calculated based on a model that 
assumes “perfect reproducibility”. Reproducibility was calculated as 
 
𝑅𝑅𝐶𝐶𝐶𝐶𝑐𝑐𝑐𝑐𝑅𝑅𝑅𝑅𝑐𝑐𝐶𝐶𝑅𝑅𝐶𝐶𝑐𝑐𝐶𝐶𝑐𝑐𝑅𝑅 =  (𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝑆𝑆𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐1 + 𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝑆𝑆𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐2)
√2 ∗ �(𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝐶𝐶𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐1)2 + (𝑍𝑍 − 𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝐶𝐶 𝐶𝐶𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶𝑐𝑐2)2 
--Eqn(4) 
Small molecules that resulted in a change of more than three negative standard deviations from 
the mean (Composite Z-score < -3) with near perfect reproducibility (Reproducibility < -0.98) 
were considered as primary hits in the HTP screening. Compound wells that positively deviated 
by 3*SD from the mean total intensity of unbound fluorescent DNA was designated as auto-
fluorescent, while compound wells that negatively deviated by 3*SD from the mean total 
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intensity of bound fluorescent DNA was designated as a quencher. The auto-fluorescent and 
quencher molecules were retained throughout the data analysis and were earmarked for further 
testing as they could be represent potential false negative or false positive molecules. Data 
visualization and analysis was carried out using both “Spotfire” and “R” packages.  
2.3.3 IC50 determination 
In both fluorescence anisotropy and electrophoretic mobility shift assays, IC50 values were 
determined by adding 45nM of Sox2-HMG to 1nM Fluorescein labelledCCND1 (~60-70% 
bound) and 0.5nM of Pax6 to 1nM of its cognate Pax6 element (~50% bound) respectively 
followed by addition of the inhibitor K6[P2Mo18O62].  This reaction mixture was further 
incubated for about an hour after which the samples were taken for reading in Spectramax M5 or 
used to run on a 12% native PAGE gel using Tris-glycine buffer for about 45 minutes at 100V. 
The IC50values were determined by fitting the data with a 4-parameter logistic model using 
sigma-plot. The 4-parameter logistic model is given as 
 
𝐹𝐹𝑐𝑐𝐹𝐹𝑐𝑐𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐 𝑅𝑅𝑐𝑐𝑅𝑅𝑐𝑐𝑅𝑅 = 𝑚𝑚𝐶𝐶𝑐𝑐 +  𝑚𝑚𝐹𝐹𝑚𝑚 −𝑚𝑚𝐶𝐶𝑐𝑐1 + 10(𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙𝐶𝐶 50−𝑚𝑚)𝐻𝐻𝐶𝐶𝑐𝑐𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝐶𝐶𝐶𝐶  
--Eqn(5) 
Here ‘Min’ and ‘Max’ refer to the maximum and minimum fraction bound protein-DNA 
complex and ‘x’ is the observed fraction bound in either the fluorescence anisotropy or EMSA 
measurements. Fraction bound is determined from the change in anisotropy, or quantification of 
fraction bound intensity of gel-shift bands whereas the logIC50 and Hill slope terms are unknown 





2.3.4 Selectivity of Various POMs using residual DNA binding activity 
measurement 
The effect of various polyoxometalates on the residual DNA-binding activity of a panel of 
transcription factors was estimated after addition of 125nM of POM to protein-DNA complexes 
that are approximately70-90% bound.  (all Sox-HMG proteins were used at 68nM concentration 
to bind to a 1nM CCND1DNA element, 0.5nM Pax6 on a 1nM Pax6 element, 68nM REST on 
1nM RE-1 element, 250nM AP2 on a HPSE element and 60nM FoxA1 on Foxa1 element). The 
residual DNA binding activities at 125nM POM is an average of three to five independent 
experiments and is reported as a percentage of the control without the inhibitor (0% residual 
binding activity would correspond to maximum inhibition, while 100% activity would 
correspond to no inhibition).The reaction mixture for electrophoretic mobility shift assays 
(EMSA) to monitor disassociation of protein-DNA complex in the presence of the inhibitor was 
performed under the same condition as the fluorescence anisotropy measurements. The samples 
were run using 1X Tris-glycine buffer on a 12% native PAGE gel for about 45 minutes at 100V. 
2.4 Limited proteolysis 
Proteolytic reactions were carried out using 50μM of Sox2-HMG in the presence and absence of 
60nM of K6[P2Mo18O62] in a 10mM Tris pH 8.0, 100mM NaCl solution. The final mixture 
contained 55μg of Sox2-HMG, 0.3μg trypsin and/or 60nM of the Dawson-POM K6[Mo18O62P2] .  
After addition of trypsin, samples were removed at regular intervals (0, 2, 30 and 60 mins) and 
boiled in denaturing SDS-PAGE loading buffer to interrupt the trypsin digestion. The proteolytic 
fragments were visualized on a NuPage Novex 4-12% Bis-Tris gel (Invitrogen) stained with 




2.5 Thermofluor assay 
Thermofluor assay is a thermal denaturation assay that compares the change in the unfolding 
transition temperature (Tm)of a protein in the presence and absence of a ligand (172). Sypro-
orange (Invitrogen), a dye which typically emits fluorescence upon binding to hydrophobic 
patches on protein surfaces was used as the fluorescent reporter to monitor the protein melting as 
the protein is heated.  Ligands that bind to the protein can  increase their thermal stability (Tm) 
as compared to the thermal stability of the protein alone. 14 μM Sox2-HMG domain solubilized 
in a 10mM Tris pH 8.0, 100mM KCl,  50uM ZnCl2, 10% glycerol, 3%DMSO buffer was initially 
dispensed in a 384 well micro-plate, followed by which increasing concentrations of the 
Dawson-POM K6[Mo18O62P2] (NSC 622124) was added. The protein-inhibitor complex was 
incubated for about an hour after which Sypro-orange was added to a final concentration of 30X 
to the solution. Sypro-orange was purchased commercially from Invitrogen as 5000X stock. The 
384 well microplates were sealed and centrifuged before being taken for thermal unfolding. 
Thermofluor measurements were recorded in a Roche LC480 PCR device with excitation at 450 
nm and emission followed at 568 nm. 
2.6 NMR sample preparation 
The solutions used for this study consisted of 0.65 mM13C, 15N isotope-labeled Sox2-HMG in 
90% H2O/10% D2O. All samples used for the two dimensional TROSY, and three dimensional 
HNCA, HNCACB and CBCAcoNH were adjusted to a pH of 7.0 in 50 mM K2HPO4/KH2PO4, 
100mM NaCl buffer. The same buffer conditions were maintained for the Sox2-Dawson-POM 
(K6[Mo18O62P2]) binding studies. The Dawson-POM K6[Mo18O62P2], was prepared as a 50mM 
stock solution in dimethylsulfoxide-d6 (DMSO-d6). Addition of POM to the free-ligand solution 
(SOX2 only) was done stepwise to achieve final concentrations of SOX2: POM ratios of 1:0.25, 
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1:0.5 and 1:1. The Sox2-HMG sample without POM was used as the reference for calculation of 
the chemical shift perturbations (∆δ). All experiments were conducted at 298K. The final DMSO 
concentration in the solution was 2% DMSO. 
2.6.1 NMR spectroscopy and data processing 
NMR experiments were performed on a Bruker AVANCE II 600 MHz NMR spectrometer 
equipped with four RF channels and a 5mm z-gradient TCI cryoprobe. The spectra were 
collected at a regulated temperature of 298K, sweep width for 1H and 15N were 9804Hz and 
2412Hz respectively. The residual HDO resonance signal was suppressed with presaturation. A 
combination of experiments was used to derive the assignments of the backbone for Sox2-HMG.  
1H and 15N resonances observed from the TROSY experiments were correlated with their 
corresponding inter- and intra-residue spin systems from 3D experiments namely HNCA, 
HNCACB and CBCAcoNH to sequentially correlate the amino acids. The raw data was 
processed using TopSpin 2.1 software, and the chemical shifts were referenced directly (1H) to 
the frequency of DSS. Peak peaking and spectral analysis was done using CARA(173).  
2.7 Docking study of the Dawson-POM [P2Mo18O62]6- with Sox2-HMG 
A crystallographic model of a Dawson-POM(C60 H50 Ag4 N12 O62 P2 W18) was obtained from the 
crystallography open database (COD: 4304834.cif) and then modified to remove the organic 
groups, retaining the Dawson structure [P2W18O62]alone using the modeling tool Avogadro 
(174). The partial charge of the ligand was calculated with quantum chemical semi-empirical 
PM6 method using MOPAC2009 software(175). The total charge of the ligand was set to -6 and 
the structure kept rigid throughout the calculation. Autodock Tools software was used in order to 
prepare Autodock4 input (pdbqt) file. H++ server was used for checking the protein structure and 
for adding hydrogens (176). Missing heavy atoms and hydrogens were added to the structure. 
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Semi-empirical assignments were performed using the PM6 method by the Mozyme function of 
MOPAC2009 program. The calculated partial charges were applied for further calculations. Two 
autodock searches were undertaken with similar settings. The first docking search was set-up so 
that the POM can explore the entire surface of the Sox2-HMG, while the second involved a 
search of the region centered around the cluster of residues M7, E66 and D69, identified by 15N 
1H TROSY NMR chemical shift perturbations. Docking calculations were carried out according 
to the Docking Server methodology(177). Solvation parameters were added with the aid of 
AutoDock tools(178). Affinity (grid) maps with 0.375 Å spacing were generated to cover both 
the NMR chemical shift identified regions as well as the entire protein surface using the 
Autogrid program(178). AutoDock settings were parameterized that the orientation of the ligand 
molecule and its initial position was set randomly. The Lamarckian genetic algorithm and the 
Solis & Wets local search strategies were employed with the docking experiment derived from 
100 runs set to terminate after2500000 energy evaluations(179). The Dawson POM molecule 
was parameterized for a rigid docking so that the bonds do not have any free torsion during the 
docking calculation. Solvent accessibility analysis of pdb structures were carried out using 
GetArea(180). 
2.8 Polyoxometalates 
Sodium phosphomolybdate Na3[PMo12O40],  Ammonium phosphomolybdate(NH4)3[PMo12O40], 
Sodium phosphotungstateNa3[PW12O40]  and Sodium metatungstate3Na2W04.9W03.xH20 were 
purchased from Sigma-Aldrich.  The Dawson-phosphomolybdate K6[P2Mo18O62] and the 
DawsonphosphotungstateK6[P2W18O62] were kind gifts from Dr. Bernold Hasenknopf (UPMC, 
France). Bulk amounts of Dawson-phosphomolybdate K6[P2Mo18O62] were also obtained by 











Sox2-HMG: Primary high-throughput screening and 














3.1 Primary screening and identification of a polyoxometalate hit  
One trancriptionally up regulated target of Sox2 is the CCND1 gene encoding cyclin D1 which is 
linked to breast cancer progression (129). A 22bp cis-regulatory element of the CCND1 gene 
was utilized for Sox2 binding, as the basis for fluorescence anisotropy based screening (Figure 
3.1A). This binding assay is linear in the range of ~130 mA units (free FAM-CCND1) to 250 
mA units (fully bound CCND1) (Figure 3.1A). The large signal window (~120mA) separating 
the Sox2 bound and unbound DNA facilitated the up scaling of the assay into a robust high-
throughput format to identify small molecule inhibitors that can specifically disrupt Sox2-
HMGDNA complex formation. The steady-state total fluorescence intensity was monitored 
throughout the binding reaction and no significant change was observed. A fluorescence 
anisotropy based DNA competition experiment was performed such that the Sox2 protein was 
just about saturated in binding (~85 -90% bound) to CCND1. Addition of unlabeled competitor 
DNA to a pre-incubated Sox2-HMG complex results in complete displacement of the labeled 
CCND1-Sox2-HMG complex and restores high anisotropy readings. At a concentration of ~2-3 
nM unlabeled CCND1, the polarization began to reduce and at a concentration of 500 nM 
competitor DNA the fluorescently labeled CCND1 was completely displaced (Figure 3.1B). 
Compound screening was carried out using the mechanistic and the challenge diversity libraries 
obtained from the National Cancer Institute Developmental Therapeutics Program (NCI, DTP, 
http://dtp.nci.nih.gov/index.html). The Mechanistic diversity library (825 compounds) is derived 
from 37,836 open compounds that have been tested on the NCI human tumor 60 cell line and 
represents compounds that exhibit a broad range of growth inhibition effects. The Challenge 
diversity set (1364 compounds) was derived from a 140,000 compound collection to create a 








A) Binding isotherm of Sox2-HMG with 1nM (FAM)-CCND1. Increasing 
concentrations of Sox2-HMG increases the fluorescence anisotropy indicating 
Sox2-HMG DNA complex formation. Data represents the average of 3 
independent titrations for a given concentration of Sox2-HMG.  
 
B) 80 nM Sox2-HMG and 1nM (FAM)-CCND1 complex was allowed to reach 






Sciclone ALH-3000 workstation in 384 well microplates and a SpectraMaxM5 plate reader. 
Measurements obtained from the positive and negative control samples in each microplate were 
used to calculate the Z’ factor for that plate. To minimize edge-related bias, the positive (4μl of 
1uM unlabeled DNA) and negative controls (4ul of 100% DMSO) for the assay were placed in 
the 2nd and 23rd columns of the microplate such that they appear equally on each of the 16 rows 
and each of the two columns (Figure 3.2A). For all the individual microplates of the mechanistic 
and challenge diversity screens, the Z’ factor was found to be > 0.60 (Figure 3.2B). Comparison 
of the replicate screens of the challenge and mechanistic diversity libraries revealed a high 
degree of correlation indicating that the screening results were reproducible (Figure 3.2C). 
Compounds with Composite Z-score < -3 and Reproducibility < -0.98 were identified as primary 
hits and were ranked based on their inhibitory activity (Figure 3.2D). In effect, the ranking 
system identified 51 compounds as potential primary hits, 33 compounds from the mechanistic 
diversity library and 18 compounds from the challenge diversity library (see Appendix E for the 
primary hit list). Many primary hits included planar and aromatic compounds with possible DNA 
intercalator activity and were therefore excluded from validation experiments. One of the 
interesting candidate molecules that emerged from the primary screening was a Dawson-type 
polyoxometalate NSC 622124 K6[P2Mo18O62], also referred to as the Dawson-
phosphomolybdate. Polyoxometalates (POMs) are usually polyanionic, nanometer sized 
compounds with well documented biological activity (138,139). Studies from a number of 
invitro experiments on polyoxometalates suggests that these class of compounds bind to proteins 
like HIV-1 reverse transcriptase, E.coli Klenow DNA pol I, and eukaryotic DNA pol β inhibiting 
nucleic acid binding activity. Therefore, the identification of a polyoxometalate scaffold as a hit 





A) Assays are carried out in a 384-well microplate depicted schematically as a heatmap 
(color coded by anisotropy values. Red color indicates higher inhibition potential while 
yellow color indicates relatively lesser inhibition). Compounds are added to each well, 
while the positive and negative controls were alternately added to the peripheral columns 
(column 2 and 23)(4).  
 
B) Duplicate screens (Screen1 and Screen2) of the challenge and mechanistic diversity 
libraries revealed a Z’ factor larger than 0.6 indicating a sufficiently large signal window 
for robust hit identification.  
 
C) Z-scores from duplicate screens correlate well highlighting the reproducibility of the 
assay.  
 
D) Screening results are shown as histograms of composite Z-scores. Primary hits were 








recently reported to selectively bind and inhibit the protein kinase CK2 and certain members of 
the kinesin family of proteins from high-throughput screening studies (159,181). Given the 
potential of POMs to selectively inhibit proteins it was decided to further study the inhibitory 
features of the Dawson-POM K6[P2Mo18O62] along with a series of other POM structures. 
3.2 Active Dawson phosphomolybdate K6[P2Mo18O62] species 
responsible for inhibition ofSox2-HMG DNA binding activity 
The Dawson-phosphomolybdateK6[P2Mo18O62]is known to undergo multiple condensation-
hydrolysis equilibria in solution depending on the pH and temperature (140). It is therefore 
possible that the Sox2-HMG domain is inhibited by a hydrolysis product of the Dawson-POM 
K6[Mo18O62P2] under equilibrium conditions. For example, phospho-molybdic Dawson-type 
POMs like (NH4)6P2Mo18O62.12H2O decompose into the lacunar Keggin-type anion 
HxPMo11O39(7-x)-,pentamolybdodiposphate HxMo5P2O23(6-x)-, phosphate and oxomolybdate 
regardless of the acidity-basicity of the solution (140). However, the degradation products 
molybdate ([MoO4]3- ) the phosphate ([HPo4]2- ), and the equivalent Keggin phosphomolybdate 
([PMo12O40]3- ) by themselves were found to be insufficient to inhibit Sox2-HMG activity 









A) Fluorescence anisotropy assay showing that degradation products of K6[P2Mo18O62], 
namely the phosphate ([HPO4]2-), the molybdate ([MoO4]2-), and the Keggin 
phosphomolybdate ([PMo12O40]3-), do not disrupt a half-saturated Sox2-HMG DNA 
complex. Ball and stick representation of the Dawson and Keggin POMs.  
 
B) Small light gray spheres are oxygen atoms and the bigger dark spheres are transition 







3.3 Preliminary selectivity studies on the Dawson-POM K6[P2Mo18O62] 
The selectivity of the Dawson-POM K6[P2Mo18O62] for Sox2-HMG was assessed in a 
preliminary experiment against an unrelated transcription factors Pax6 using electrophoretic 
mobility shift assays (EMSAs). EMSA experiments were performed such that the Pax6 and 
Sox2-HMG proteins are incubated with their respective cognate fluorescently labeled DNA 
elements at concentrations resulting in a fractional binding of50-70% prior to the addition of the 
Dawson-POM. It was found that K6[Mo18O62P2], .inhibits Sox2-HMG DNA binding with an IC50 
value of 98.6±22.1 nM, while Pax6 did not show any inhibition at all (Figure 3.4). Addition of 
unlabeled Pax6 consensus DNA sequence (100nM DNA element) serves as the positive control 
for complete inhibition of Pax6-fluorescein labeled DNA complex (Appendix F). This 
preliminary selectivity study demonstrated thatK6[Mo18O62P2] exhibits varying inhibition 
profiles against unrelated TF structural classes suggesting that K6[Mo18O62P2] discriminates 






























A) Gel-shift assays using varying POM concentrations shows that K6[P2Mo18O62] selectively 
inhibits Sox2-HMG with an IC50 value of 98.6 ±22.1 nM.  
 
B) Representative EMSA experiment showing dose-dependent titrations of K6[P2Mo18O62] 
with 40nM Sox2-HMG and 1nM CCND1 (~50-70%fraction bound) and 0.5nM Pax6 and 










3.4 The Dawson-POM K6[Mo18O62P2] physically interacts with the 
Sox2-HMG domain 
A series of secondary assays were performed to verify the interaction of the Dawson-POM 
K6[P2Mo18O62]with the Sox2-HMG domain. Firstly, limited trypsin digestion of Sox2-HMG in 
the presence and absence of the Dawson-POM revealed that the POM confers sustained 
resistance to proteolytic digestion, whereas the Sox2-HMG alone is degraded more rapidly 
(Figure 3.5A). Secondly, a comparison of the thermal unfolding of the Sox2-HMG domain in the 
absence and presence of the Dawson-POM K6[Mo18O62P2], revealed differences that can be 
attributed to a stabilization effect of the POMs on the melting profile of Sox2-HMG. The 
addition of increasing concentrations of the Dawson-POM K6[Mo18O62P2] transformed the 
melting profile and increased the unfolding transition suggesting that the Dawson-
phosphomolybdate directly binds and stabilizes the Sox2-HMG domain (Figure 3.5B). The 
thermal denaturation profiles of Sox2-HMG alone  and the Sox2-HMG inhibitor complex at 1:1 
ratio could not be modeled reliably with Van’t Hoff  models and hence parameters like enthalpy 
and melting temperature could not retrieved (182). However, the nature of the melting profile 
provided sufficient qualitative information to suggest a physical interaction between the 
Dawson-POM K6[Mo18O62P2] and Sox2-HMG. It must also be mentioned at this context that 
attempts to measure the binding affinity of the POM to Sox2 by ITC resulted in a failure to 
obtain titrations with good curvature. This loss of binding curvature in ITC experiments is well 
documented and is known to occur for ligands with a very high binding affinity. With very tight 
binding events in the lower nanomolar range (1-100nM) there can be a loss of curvature and 
accurate estimates of binding constants cannot be obtained as the range of binding constants that 









A) Limited proteolysis reveals that interaction of Sox2with K6[P2Mo18O62] confers 
resistance to proteolytic digestion by trypsin. Sox2-HMG was incubated with trypsin in 
the presence (lanes 3-6) and absence (lanes 8-11) of the Dawson-POM K6[P2Mo18O62]. 
Reactions were stopped after different time points and analyzed by 4-12% SDS-PAGE. 
Molecular weight markers are added in lanes 1 and 7. Lane 2 contains the Sox2-HMG 
incubated for 60min but not subjected to trypsin digestion.  
 
B) Thermal melting profiles of Sox2-HMG monitored in the presence of Sypro-orange with 





presumable from the IC50 estimation (98.6±22.1nM) that the binding affinity could potentially be 















































4.1 Studies of Sox2 Dawson-POM K6[P2Mo18O62] interaction by NMR 
To understand the inhibitory mechanism and to facilitate the follow-up chemistry aimed at 
optimizing the selectivity and potency of the Dawson-POM K6[P2Mo18O62], multidimensional 
NMR experiments were carried out. To assign backbone-resonances 13C and 15N double-labeled 
Sox2-HMG domain was recombinantly purified and HNCA, HNCACB, and CBCAcoNH 
spectra were recorded for this sample. Approximately 80% of the 114 residues of the Sox2-HMG 
construct could be unambiguously assigned, with the unassigned residues predominantly 
belonging to the largely flexible N- and C-termini. Importantly, residues comprising the helical 
core of the Sox2-HMG domain and DNA contacting residues could be reliably assigned. To 
study the effect of POM binding to Sox2-HMG, 15N 1H TROSY measurements were recorded in 
the absence and presence of the Dawson-POM K6[P2Mo18O62]. When the Dawson-POM 
K6[P2Mo18O62]was added additively to 0.65mM protein, the backbone resonances were observed 
to selectively shift distinct peaks, further corroborating a direct interaction with the Sox2-HMG 
and suggesting a structurally defined binding region (Figure 4.1). Chemical shift perturbations 
from these experiments were quantified by using an overall weighted plot(∆δ = [∆δ2HN + 
(0.2∆δN)2]1/2 )(184,185). The combined chemical shift is displayed on a Sox2 model which was 
derived from a Sox2-Oct1/DNA (PDB:1GT0) crystallographic structure (Figure 4.2). Based on 
the distribution of the weighted chemical shift values, residues were classified into (i) those that 
undergo significant chemical shift changes (∆δ ≥ 0.065 ppm), (ii) those that undergo moderate 
chemical shift changes(0.04ppm ≥ ∆δ< 0.065 ppm) and (iii) those with low chemical shift 
changes (∆δ< 0.04 ppm) (Figure 4.3). The residues Met7, His29, Glu66 and Asp69 were shifted 
most significantly (numbering based on Sox2-model in the crystal structure 1GT0). Among 







Superimposed spectra of two-dimensional TROSY spectra of free Sox2 (pink) and Sox2 
bound to POM (blue).Each cross-peak represents a bonded N-H pair. The axes correspond to 
the chemical shifts of N and H atoms in ppm (parts per million).The peaks that undergo 

















The weighted change in chemical shift perturbations (∆δ = [∆δ2HN + (0.2∆δN)2]1/2 ) 
obtained from the 15N 1H TROSY experiments are mapped on the entire Sox2-HMG 
surface. Residues which are significantly shifted are depicted by an arrow. The colored 
spectrum bar displays the extent of NMR chemical shift perturbations in ppm. 










Changes in chemical shift (∆δ = [∆δ2HN + (0.2∆δN)2]1/2 )upon POM binding is plotted 
against the Sox2 amino acid sequence (numbered according to Sox2: 1GT0). Threshold 
windows indicating Significant (S), Moderate (M) and Low (L) chemical shift 
perturbations are depicted as straight lines. Green colored bars indicate residues which 
have been implicated in direct binding to POM based on docking studies. Residues that 
are unchanged in TROSY are indicated with an asterisk (*). Unassigned residues are 
colored in light blue and given arbitrary negative chemical shift values solely for data 
visualization purposes. Sox2-HMG residue sequences involved in DNA binding are 
colored in blue. Secondary structural elements like alpha helices are named and colored 




proximity to the DNA binding region (Figure 4.2). Among the significantly shifted residues 
Met7, Glu66 and Asp69 are in spatial proximity whereas His29 is located distantly in loop 1 of 
the HMG’s major wing (Figure 4.2). The structural role of these significantly perturbed residues 
in POM binding was investigated further by docking studies (described in the section below) and 
was aided by comparison with solution structures of Sox17 (PDB:2YUL), Sox5 (PDB:1I11) and 
the DNA bound structure of Sox2 (PDB:1GT0). Buried core residues like Trp13, Ala22, Lys27 
and Ile33 which cause the stacking of helices 1 and 2 of the HMG major wing, were found to be 
least perturbed upon POM binding, suggesting that the structural integrity of the HMG domain is 
retained upon inhibitor binding. A majority of the Sox2-HMG residues, however, exhibited 
moderate chemical shift changes suggesting a POM induced reorganization of the backbone 
(Figure 4.3). It is well documented that residues showing 15N 1H TROSY shifts do not 
necessarily constitute the POM binding site but that such perturbations may also occur at a 
distance from the actual binding site via indirect and allosteric effects (186,187). To further 
investigate Sox2-HMGPOM interactions, the chemical shift perturbations were employed to 
constrain ligand binding sites on the Sox2-HMG surface by docking studies. 
4.2 Preferential binding site of the Dawson-POM K6[P2Mo18O62] on the 
Sox2-HMG surface 
In order to identify the site of interaction of the Dawson-POM K6[P2Mo18O62] with the Sox2-
HMG, two autodock searches were undertaken. First, a blind docking search was set-up such that 
the POM can explore the entire surface of a Sox2-HMG model derived from Sox2/Oct1/DNA 
crystal structure (70). The second search was restrained by drawing a grid in the spatial zone 
defined by the cluster of the residues Met7, Glu66 and Asp69 which were identified as being 
significantly shifted from 15N 1H TROSY NMR. Both, the blind and NMR chemical shift based 
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docking calculations identified a common docking site showing that this binding site is highly 
preferred by POM. The binding pocket is formed by the C-terminal helix-3 and the N-terminal 
region of the minor wing of the L-shaped Sox2-HMG structure (Figure 4.4A). A comparison of 
the Sox2-POM docked structure with the X-ray structure of ternary Oct1.Sox2.DNA complex 
(PDB code: 1GT0) reveals that the binding of POM to this site would interfere with the negative 
phosphate backbone of DNA by competing with the neighboring positively charged residues in 
Sox2 (Figure 4.4B).   
As the ligand surface is negatively charged, the calculated docking energy was found to be very 
low (-10.6 kcal/mol) corresponding to a binding affinity of ~50 nM. Such a tight binding affinity 
presumably also explains the difficulty in obtaining reliable ITC curves as discussed earlier. The 
negatively charged surface of POM can form many favorable electrostatic interactions within the 
binding cavity of Sox2 in the docked complex geometry (Figure 4.5A). The binding cavity is 
formed mostly by basic residues: Lys4, Arg5, Arg15, His63 and His67. The positively charged 
side chains of these residues can form hydrogen bonds and/or electrostatic interactions with the 
negatively charged oxygens of POM. The backbone amide of Lys4 forms an additional hydrogen 
bond with POM (Figure 4.4A). An alternative expanded snap-shot of the docked configuration is 
provided in Appendix G to provide adequate visualization of the range of electrostatic and 
hydrogen bond interactions. In accordance with the docking studies, the positively charged 
residues Lys 4, Arg5 and Arg15 exhibit moderate chemical shift changes while His63 and His67 
exhibit insignificant perturbation. Solvent accessibility analysis of DNA free Sox2-HMG (1GT0) 
reveals that His63 (only 13% solvent exposed) could be classified as a buried residue, while 
His67 is (30% solvent exposed) a partially exposed residue (Figure 4.5B). The lack of significant 











A) The lowest energy Sox2-HMG-POM complex structure from the Autodock searches 
shows the POM positioned within a pocket in the minor wing of the Sox2-HMG 
structure. Lys4, Arg5, Arg15, His63 and His67 are potentially involved in electrostatic or 
hydrogen bond interactions. Glu66 can donate hydrogen bond in a protonated form. 
Leu59, Leu62, Met7 and Val3 contribute to shaping the hydrophobic cavity. The Sox2 
structure is shown as cartoon and the interacting amino-acids are shown as sticks. 
Dawson-POM K6[P2Mo18O62] is also shown in stick representation. Hydrogen bonds and 
electrostatic interactions less than 3.5Å are shown in red dots. Residue numbering is 




















B) Comparison of the docked model from Figure 4.4A with the Sox2-DNA complex X-ray 
structure (1GT0) reveals that binding of POM to this site would directly interfere with 
DNA binding due to charge repulsion. The Sox2-DNA complex structure is shown as 
cartoon and the interacting amino-acids of Sox2 is depicted as sticks. The Dawson-POM 











chemical environment around solvent inaccessible residues. The single acidic residue in the 
POM binding cavity Glu66, was found to be most strongly shifted following POM addition in 
the TROSY measurements (Figure 4.2 & Figure 4.3). Even though a protonated state of Glu66 
cannot be ruled out due to a slightly altered pH microenvironment, such a state at neutral pH is 
unlikely. It is more conceivable that POM binding repels Glu66 due to unfavorable negative 
charges causing it to structurally re-orient with respect to the unbound Sox2-HMG.Asp69 is a 
residue strongly perturbed in TROSY but is not present in the POM docking site. Asp69 is 
located in the C-terminal of helix 3 which is a region subject to inherent conformational changes 
due to protein flexibility (Figure 4.4A).This is evident from NMR studies of Sox4 and Sox5 
which reveal that the C-terminus comprises the most dynamic region of the protein (66,188). 
Following DNA binding however, the C-terminus is markedly rearranged to participate in the 
DNA interaction(71). Thus, the pronounced perturbation detected for Asp69 likely illustrated the 
dynamics of this region and its structural adjustments accompanying molecular recognition 
events. The strongly perturbed His29 is also a residue that is not located in the POM docking site 
but is positioned in loop 1, connecting helices 1 and 2 (Figure 4.3). This loop was found to 
exhibit the most pronounced Cα RMSD (Root mean square deviation) deviation within the 
helical core of the HMG domain when the DNA-bound Sox17 was compared with Sox5 and 
Sox17 NMR structures (71).By inspecting the different conformers of the solution structure of 
Sox17 (PDB: 2YUL), it is evident that the N-terminal region of the minor wing is very dynamic 
and includes conformations where the unstructured minor wing N-terminus approaches loop1 
indicating a potential for cross-talk between these regions. The Sox2-HMG construct employed 
in this study contains an N-terminus extended by 13 amino acids as compared to the homologous 







A) Interaction surface of Sox2-HMG colored by PM6 partial charges without and with 
docked ligand (blue – positive, red – negative). 
 
B) Solvent accessibility per residue of DNA free Sox2-HMG structure (PDB: 1GT0) is 
plotted against the Sox2-HMG sequence and bars colored to depict their corresponding 






would come into contact with His29 in loop1 due to conformational reorganization induced by 
POM binding. In addition to the charged amino acids, several hydrophobic residues like Val3, 
Met7, Leu59 and Leu62 shape the cavity of the POM docking site (Figure 4.4A). Consistently, 
Met7 exhibited a significant chemical shift in the TROSY experiment while Val3, Leu59 and 
Leu62 are moderately affected. Together, NMR and docking studies suggest a model illustrating 



































5.1 Selectivity studies on the inhibition of Sox-HMG family of TFs by 
polyoxometalates 
To assess the selectivity of a panel of POMs, extensive experiments were carried out on different 
members of the Sox-HMG family as well as with transcription factors of unrelated structural 
classes namely Pax6, REST, FoxA1and AP2 (Full length protein sequences were used for FoxA1 
and AP2). Pax6 contains a bi-partite paired DNA binding domain, the REST has eight Cys2/His2 
Zinc-finger DNA binding domains, Ap2 has a beta-sheet fold and FoxA1 has a forkhead/winged 
helix DNA binding domain (167,189-191). In total, the residual DNA binding activities of 15 
different TFs was estimated against a panel of 15 different polyoxometalates. The panel of 
polyoxometalates that were tested could be broadly classified into the “Keggin” POMs the 
“Dawson” POMs, and other simpler POMs like sodium metatungstate and decavanadate. The 
details of the type of POMs employed in the study, including the type of organic modification is 
provided in a table along with structures of organic Dawson POMs (Figure 5.1 & Table 
5.1).Keggin POMs exert lowered inhibition on the Sox-HMG members as compared to the 
Dawson POM leading to the observation that the size of inhibitor polyoxometalate is an 
important consideration in the inhibition of the Sox-HMG family (Figure 5.2). To determine 
selectivity, fluorescence anisotropy (all Sox-HMGs, REST, AP2 and FoxA1) and EMSA 
experiments (Pax6) were performed such that the proteins were incubated with their respective 
cognate fluorescently labeled DNA elements at concentrations resulting in a fractional binding of 
70-90%, prior to the addition of various POMs. The residual DNA binding activity is estimated 
from three to five independent experiments and is reported as a percentage of the control without 
the inhibitor (0% residual binding activity would correspond to maximum inhibition, while 




Figure 5.1  
The regioselective (α1/α2) organic side chains of tin substituted Dawson POMs 


























Table 5.1 Panel of 15 POMs screened for inhibition of DNA binding activity of 15 transcription 
factors 




   g/mol 
km488 α1 P2W17O66SnC24H34N4(NC16H36)7 Dawson Trp-Ala-Leu 6438 
km454 α1 P2W17O66SnC22H32 (NC16H36)7 Dawson Phe-Ala-Leu 6356 
km683 α1 P2W17O61SnC4H10(NC16H36)6 Dawson Aliphatic 5794 
km643 α2 P2W17O61SnC4H10(NC16H36)6 Dawson Aliphatic 5794 
km336 α2 P2W17O62SnC6H8N4(NC16H36)7 Dawson Aliphatic 6089 
CP11 α1 P2W17O62SnC6H8N4(NC16H36)7 Dawson Aliphatic 6089 
km393 α2 P2W17O62SnC6H11N4O(NC16H36)7 Dawson Aliphatic 6135 
km359 α2 P2W17O62SnC16H23N3O2(NC16H36)7 Dawson Val-Val-Val 6357 
km633 H3V10O28(NC16H36)3 Decavandate Vanadium 1688 
km144 α2 P2W17O62SnC3H4O2(NC16H36)6 Dawson Cyclic aliphatic 5810 
DpomMo K6[Mo18O62P2] Dawson None 3016 
DpomW18 K6[W18O62P2] Dawson None 4597 
KeggMo [PMo12O40]3- Keggin None 1892 
KeggW [PW12O40]3- Keggin None 2946 












5.1.1 Unmodified Dawson-POM K6[P2Mo18O62] and decavandate H3V10O28 are 
relatively selective TF inhibitors 
The average residual DNA binding activity of 15 different TFs against a panel of POMs from 
three-five independent experiments was used in a clustering analysis using an “R heatmap.2” 
package. From the clustering analysis it could be clearly observed that the Keggin and Dawson 
class of polyoxometalates exhibit a marked dichotomy in their selectivity and inhibition potential 
of the Sox-HMG family of transcription factors (Figure 5.2). The Dawson POMs were found to 
be highly potent in their inhibition profiles of not only the Sox-HMG members but also other TF 
families like FoxA1, REST and AP2 (Table 5.2). Modified organic Dawson POMs were tested 
under the assumption that their functionalized organic side-chains would be capable of exploiting 
subtle differences in the Sox-HMG domain sequences to exhibit Sox family specific inhibition. 
Contrary to expected behavior, the modified Dawson polyoxometalates did not bring about a 
commensurate change in selective discrimination of the HMG family members. The modified 
Dawson polyoxometalates invariably amplified the inhibitory potency of the pristine “Dawson” 
scaffold against various Sox-HMG members (Figure 5.3). The potency of the organically 
modified Dawson-POMs in inhibiting the Sox-HMG family merits investigation through 
crystallographic/NMR methods for a better understanding of the physico-chemical nature of 
these interactions. The organically modified Dawson-POMs while being moderately effective 
against AP2 was also found to be very effective against FoxA1.  Among the transcription factors 
tested it was observed that Pax6 was the most inert to POM treatment, with a majority of the 
POMs not having any effect on the Pax6 paired domain activity tested using EMSA (Appendix 
H).  The only POMs that were relatively effective in inhibiting Pax6 activity were KM393, 





A heatmap of the average residual DNA binding activity (‘value’ in %) of 15 different TFs 
against a panel of 15 POMs, clustered by their inhibition profiles (Red color indicates higher 
inhibition, while yellow color indicates relatively lesser inhibition). Keggin POMs exert lowered 
inhibition on the Sox-HMG members leading to the observation that the size of polyoxometalate 
is an important consideration in the inhibition of the Sox-HMG family. Inhibitor compounds are 
color coded according to their polyoxometalate class as indicated in Table 5.1 (Dawson, Keggin 






 Dawson Other Keggin Salt 
 KM144 DpomW18 DpomMo MetaW KM633 KeggMo KeggW Namolyb 
Pax6 100 ± 0 93 ± 5 77 ± 2 99 ± 1 64 ± 5 93 ± 2 56 ± 4 100 ± 0 
AP2 19 ± 6 35 ± 16 13 ± 2 10 ± 11 74 ± 21 83 ± 14 60 ± 17 76 ± 19 
REST 6 ± 5 15 ± 3 57 ± 26 11 ± 4 41 ± 6 88 ± 7 59 ± 26 76 ± 31 
Foxa1 9 ± 5 48 ± 15 26 ± 9 11 ± 2 81 ± 13 77 ± 19 59 ± 9 96 ± 6 
Sox2 7 ± 5 12 ± 10 25 ± 21 8 ± 3 41 ± 16 95 ± 5 81 ± 9 95 ± 4 
Sox4 9 ± 10 17 ± 4 54 ± 19 15 ± 9 70 ± 12 91 ± 17 89 ± 8 91 ± 9 
Sox5 13 ± 8 12 ± 4 24 ± 15 12 ± 8 73 ± 24 99 ± 3 84 ± 5 95 ± 4 
Sox6 10 ± 5 11 ± 4 14 ± 6 17 ± 3 77 ± 9 95 ± 6 80 ± 8 90 ± 9 
Sox7 6 ± 5 13 ± 5 74 ± 18 8 ± 2 69 ± 19 81 ± 27 95 ± 5 98 ± 3 
Sox8 9 ± 5 14 ± 2 29 ± 16 11 ± 4 56 ± 10 96 ± 2 89 ± 5 92 ± 2 
Sox9 10 ± 8 11 ± 9 43 ± 8 10 ± 5 48 ± 11 94 ± 5 85 ± 7 96 ± 5 
Sox10 11 ± 2 14 ± 6 37 ± 14 16 ± 8 46 ± 22 96 ± 2 87 ± 8 94 ± 6 
Sox11 12 ± 6 25 ± 12 53 ± 33 10 ± 4 59 ± 27 97 ± 3 92 ± 6 96 ± 4 
Sox17 28 ± 39 12 ± 8 43 ± 39 9 ± 7 48 ± 25 92 ± 3 93 ± 6 94 ± 5 






KM488 KM454 KM683 KM336 KM643 CP11 KM393 KM359 
Pax6 75 ± 1 86 ± 1 82 ± 2 81 ± 2 70 ± 2 76 ± 4 59 ± 6 56 ± 9 
AP2 21 ± 10 6 ± 4 15 ± 10 17 ± 15 39 ± 17 45 ± 20 30 ± 15 55 ± 22 
REST 10 ± 5 9 ± 2 6 ± 6 4 ± 3 6 ± 4 4 ± 6 9 ± 3 10 ± 5 
Foxa1 12 ± 16 4 ± 5 10 ± 9 4 ± 5 9 ± 4 10 ± 7 8 ± 7 18 ± 13 
Sox2 8 ± 3 6 ± 4 4 ± 5 7 ± 6 6 ± 4 12 ± 6 6 ± 5 10 ± 2 
Sox4 14 ± 10 12 ± 6 4 ± 3 6 ± 6 10 ± 2 18 ± 3 12 ± 7 4 ± 4 
Sox5 11 ± 7 10 ± 8 8 ± 6 9 ± 8 6 ± 6 12 ± 5 10 ± 5 10 ± 5 
Sox6 7 ± 8 13 ± 3 2 ± 3 9 ± 5 11 ± 4 10 ± 3 7 ± 4 11 ± 4 
Sox7 8 ± 2 7 ± 6 3 ± 4 2 ± 1 8 ± 6 7 ± 3 9 ± 2 5 ± 4 
Sox8 12 ± 6 8 ± 4 7 ± 5 12 ± 7 6 ± 4 11 ± 7 6 ± 7 7 ± 4 
Sox9 10 ± 6 10 ± 8 6 ± 6 10 ± 5 7 ± 5 10 ± 8 15 ± 5 11 ± 8 
Sox10 15 ± 3 7 ± 5 8 ± 6 9 ± 7 10 ± 6 5 ± 5 10 ± 5 11 ± 8 
Sox11 12 ± 4 10 ± 5 9 ± 6 5 ± 10 9 ± 7 11 ± 3 8 ± 5 10 ± 5 
Sox17 9 ± 8 8 ± 7 5 ± 5 6 ± 5 7 ± 3 10 ± 4 7 ± 5 7 ± 3 
Sox18 14 ± 5 14 ± 8 10 ± 5 9 ± 7 2 ± 3 17 ± 8 3 ± 3 10 ± 4 
       Namolyb 
Table 5.2 Residual DNA binding activity (in %) of 15 TFs against 15 different POMs from 








A 3D bar plot depiction of the selectivity study of 15 TFs against a panel of 15 POMs from 








Dawson-POM K6[P2Mo18O62] and the decavanadate, KM633 (H3V10O28) were the only two 
POMs that exhibited a rather diverse and therefore relatively selective inhibitory pattern against 
the panel of 15 TFs (Figure 5.4).The diversity between the Dawson-POM K6[P2Mo18O62] and the 
decavanadate KM633 (H3V10O28) is most evident from their inhibiton potential of the same Sox-
HMG member. For example, the Dawson-POM K6[P2Mo18O62] inhibits Sox6 so that it retains 
only 14± 6 % of its DNA binding activity, whereas decavanadate is least effective against Sox6 
retaining 77±9%of its DNA binding activity highlighting the diversity in the inhibitory potential 
between the Dawson-POM and the decavanadate against a Sox-HMG member (Table 5.2).It 
must be mentioned at this juncture that decavandates are known to have established properties of 
interaction with redox and hydrolytic enzymes and is also known to affect calcium pumps and 
the function of actin and myosin(138). However, one of the limitations of the decavandate, is that 
it has a limited chemistry with respect to being modified by organic groups when compared to 
the Dawson-POMs(139).The selectivity potential of polyoxometalates is most evident from the 
inhibition potential of the same polyoxometalate against different Sox-HMG members. For 
example, it can be observed that the group F members Sox7 and Sox18 were the most inert of all 
Sox-HMG proteins tested against K6[P2Mo18O62], retaining74 ± 18 %  and 61 ± 14 % of their 
DNA binding activity respectively, highlighting the differential interaction between different 
Sox-HMG members against the same inhibitory polyoxometalateK6[P2Mo18O62](Table 5.2 and 
Figure 5.4). The inhibition potential of K6[P2Mo18O62]on Group F members Sox7 and Sox18 
differs significantly from inhibition of the group B member Sox2,as evaluated by a Student’s t-
test (Appendix I). This relatively selective interaction behavior of K6[P2Mo18O62] could not 
however be extended to the other Group F member Sox17 because of the high experimental 
noise in Sox17 DNA binding activity estimation. Sox17 was found to retain 43 ± 39% of its 
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DNA binding activity with K6[P2Mo18O62] treatment. This experimental noise could be because 
of potential intrinsic instability of Sox17 over the course of experiment (eg; gradual loss of DNA 
binding activity due to mis-folding). Knowledge of the putative binding site of K6[P2Mo18O62] on 
Sox2 reveals potential reasons for the observed differential interaction of this POM with the 
other Group F members Sox7 and Sox18. Firstly, multiple sequence alignment reveals consistent 
differences between the Group F members (Sox7 andSox18) and Sox2 in atleast six out of ten 
amino-acid positions that has been proposed to bind to the Dawson-POM K6[P2Mo18O62] (Figure 
5.5). A distinct relationship between the substitution of an amino-acid and it’s corresponding 
effect on K6[P2Mo18O62] binding to different Sox-HMG family members can be discerned by 
observing that the amino-acid position corresponding to Val3 andLeu62 (PDB: 1GT0 
numbering) in Sox2 is replaced by Ile3and Gln62 in Sox7 and Sox18. Val3 along with Met7, 
Leu59 and Leu62 are involved in shaping the hydrophobic cavity of Sox2 for the Dawson-POM 
K6[P2Mo18O62] to bind (Figure 4.4A). It can be envisaged that substitution of Val3 and Leu62 in 
Sox2 by the homologous amino-acids (Ile3 and Gln62) in Sox7 and Sox18 leads to an altered 
shape in the hydrophobic Dawson-POM K6[P2Mo18O62] binding cavity. Similarly, the 
substitution of Lys4 and Arg15 in Sox2 by Arg4 and Lys15 in Sox7 and Sox18 could be 
envisaged to provide an altered electrostatic and hydrogen bonding environment for the 
K6[P2Mo18O62] binding. Thus it can be expected the pristine Dawson-POM K6[P2Mo18O62] is 












A 2D bar plot extract of figure 5.3 depicting the diverse and relatively selective inhibition effect 
of the Dawson-POM K6[P2Mo18O62] and KM633 (H3V10O28) in inhibiting a panel of 15 TFs 












Multiple sequence alignment of the core HMG-domain reveals differences between the 
Group F  members (Sox7 and Sox18) and Sox2  in 6 out of 10 amino-acid positions proposed 
to be involved in K6[P2Mo18O62] binding with Sox2. Residues potentially involved in 
K6[P2Mo18O62] binding based on docking studies with Sox2 are indicated by red dots. 
Homologous Sox-HMG residue positions involved in POM binding that exhibit consistent 
differences between the Group F members (Sox7 andSox18) and Sox2 across the sequence 

































6.1 Summary of Results 
1. A high throughput fluorescence anisotropy screen of a library of 2,189 structurally and 
mechanistically diverse compounds for inhibitors of Sox2-HMG DNA binding activity 
resulted in the identification of a nanomolar wells-Dawson-Polyoxometalate 
K6[P2Mo18O62] inhibitor. 
2. The Dawson-Polyoxometalate K6[P2Mo18O62] physically interacts with the Sox2-HMG 
domain and  inhibits DNA binding activity with an IC50 of  98.6±22.1 nM. 
3. Preliminary selectivity studies of K6[P2Mo18O62] revealed that this Dawson-POM can 
discriminate between Sox2-HMG, Pax6-paired domain and the REST C2H2 DNA 
binding domain surfaces in its inhibitory potential. 
4. NMR and docking studies suggest that K6[P2Mo18O62] binds to a binding pocket formed 
by the C-terminal helix-3 and the N-terminal region of the minor wing of the L-shaped 
Sox2-HMG structure. 
5. A comprehensive selectivity panel consisting of 15 different TFs against a panel of 15 
different polyoxometalates revealed a marked dichotomy in the selectivity and inhibition 
potential of the Dawson and Keggin polyoxometalates. 
6.  Dawson polyoxometalates modified with organic moieties were found to invariably 
amplify the inhibitory potency of the pristine “Dawson” scaffold against all the Sox-




6.2 Mechanism of Sox-HMG inhibition by the Dawson-POM 
K6[P2Mo18O62] 
The DNA binding domains of transcription factors have so far been considered too impervious to 
be tackled as drug targets although upregulated transcription factors are a major cause of cancer 
and other diseases (21,24,192). A Dawson-POM K6[P2Mo18O62] has been identified as an 
unconventional but potent scaffold to inhibit the DNA binding activity of Sox2 from this study. 
Based on NMR and autodock experiments, a structural mechanism of inhibition of Sox2-HMG 
by the Dawson-POM K6[P2Mo18O62]  has been proposed. Firstly, a comparison of the Sox2-
POM docked structure with the X-ray structure of ternary Oct1.Sox2.DNA complex (PDB code: 
1GT0) reveals that the binding of POM to this site would interfere with the negative phosphate 
backbone of DNA by competing with the neighboring positively charged residues in Sox2 
(Figure 4.4B and Figure 6.1). Secondly, the binding of POM could induce structural 
rearrangements of the N-terminal Sox2-HMG minor wing favoring a closed conformation of the 
major and minor wings. Taken together, the POM induced repulsion of the negatively charged 
DNA backbone followed by a preferential closure of the wings of the HMG domain would cause 
structural rearrangements that would result in exclusion of the DNA from the HMG scaffold. 
The mode of interaction of the Dawson-POM K6[P2Mo18O62] involves predominantly 
electrostatic interactions at the pocket just outside of the DNA binding region but still adequately 
positioned to interfere with the DNA binding residues to effectively compete for the negatively 
charged DNA backbone (Figure 6.1).While obtaining an atomic structure of a Sox2-HMG/POM 
complex would provide valuable insights to test the proposed structural mechanism of POM 
inhibition, it must be mentioned that one of the challenges that the current study faced was 





















polyoxometalates K6[P2Mo18O62] or K6[P2W18O62]. Crystallization of Sox2 with K6[P2Mo18O62] 
had the problem that the Dawson phosphomolybdate K6[P2Mo18O62]  is intrinsically unstable for 
longer time periods in aqueous buffers and breaks down into fragmentary POMs, while the 
relatively hydrolysis stable Dawson phoshpotungstate K6[P2W18O62] had the shortcoming of 
being insoluble in aqueous buffers at higher concentrations that would be necessary for 
crystallization.  
6.3 Future experiments to test the mechanism of Sox2-HMG inhibition 
by the Dawson-POM K6[P2Mo18O62] 
The biophysical mechanism that has been proposed to explain the inhibition of Sox2-HMG by 
K6[P2Mo18O62] can be tested by a series of precise biochemical mutation experiments. Firstly, 
critical residues in Sox2-HMG that are potentially responsible for making hydrogen bond 
/electrostatic contacts with K6[P2Mo18O62]  like Lys4, Arg5, Met7, Arg15, His63 and His67 can 
be mutated into alanine by either point or combinatorial mutations. These mutations can be 
envisaged to have only a minimal effect on the DNA binding activity of Sox2-HMG, but could 
have a significant impact on the inhibitory potential (higher IC50 values) of K6[P2Mo18O62] and 
can be verified from fluorescence anisotropy experiments. Conversely, mutations of His29 and 
Asp69 into alanine should not have any direct effect on the inhibitory potential of K6[P2Mo18O62] 
as these residues are expected to be perturbed only due to allosteric/secondary binding effects.  
Summarily, the above biochemical mutation studies can be expected to validate or falsify the 
biophysical mechanism proposed in this study. Secondly, stopped flow kinetics experiments or 
surface plasmon resonance based experiments could be carried out to estimate parameters like 
Kon and Koff  in the presence and absence of the inhibitor to assess whether the inhibitory 
mechanism is competitive, non-competetive or un-competetive type inhibition. 
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6.4 Assessment of the selectivity of Dawson-polyoxometalates 
Firstly, a detailed investigation on a panel of different transcription factors against an expanded 
set of various polyoxometalates reveal that the Keggin and Dawson class of polyoxometalates 
exhibit a marked dichotomy in their selectivity. This leads to the observation that the size of 
inhibitor polyoxometalate is an important consideration in the inhibition of the Sox-HMG 
family. Secondly, the functionally modified Dawson POMs do not show any selective inhibition 
pattern when tested against a panel of transcription factors.  The amplified potency of the 
modified Dawson POMs clearly seem to be due to physical interactions of the organic side 
chains with the transcription factors when compared to the potential of the unmodified Dawson 
polyoxometalate alone. While the idea of achieving selectivity using derivatized POMs to 
various classes of DNA binding is in principle a promising approach, the outcome of testing a 
limited sub-set of modified Dawson POMs indicate substantial methodological challenges 
involved in achieving selectivity against different TF DNA binding domains. Another important 
methodological issue that should be considered in these studies is the effect of the buffer 
composition. A recent study on HIV-1 protease inhibition by organic Dawson POMs has shown 
that inhibitory profiles are to a large extent affected by the buffer composition, namely the 
concentration of DMSO and the type of counter ion (160). Future studies could be performed to 
take this into account when studying TF inhibition by different Dawson-POMs. The inhibitory 
chemistry of the organically modified Dawson-POMs towards the Sox-HMG family though 
challenging, merits further investigation through crystallographic/NMR methods for a better 
understanding of the physico-chemical nature of these interactions. Such a detailed structural 
study may help in exploiting the utility of the Dawson polyoxometalate scaffold for inhibition of 
a wide variety of transcription factors. Thirdly, the Dawson scaffold K6[P2Mo18O62]  seems to 
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exhibit a subtle difference in inhibition of Sox7 and Sox18 over other Sox-HMG members like 
the Group B Sox2 (Figure 5.4 and Table 5.2). Based on previous NMR and auto-docking studies 
it was observed that there are consistent differences between Sox7 and Sox18 with Sox2 in six 
out of ten amino-acid positions known to bind to the Dawson-POM K6[P2Mo18O62] leading to a 
subtle change in the surface interaction chemistry potentially accounting for the observed 
difference in the inhibition of Sox2 as compared to Sox7 and Sox18 (Figure 5.5). 
6.5 Potential Strategies that can be adapted from polyoxometalate 
based inhibition chemistry to target the DBDs of Transcription factors 
Traditional drug discovery approaches from high throughput chemical screening of compound 
libraries on a target by target basis followed by development of primary hits into leads by 
organic synthesis have only been modestly successful in the evolution of general strategies for 
targeting different structural classes of transcription factors. Even though targeting the DNA 
binding domain of TFs is challenging, evolving a core inhibitor chemistry that can be 
functionally customized to specifically target the DNA binding domains of different of TFs will 
have a significant impact in the pharmacology of targeting TFs. The development of click 
chemistry to incorporate a range of organic substrates in tin substituted Dawson POMs by 
reacting with monovacant α1/α2-[P2W17O61]10- lacunary POMs has expanded the horizon of 
organic modifications that could be achieved in polyoxometalate chemistry(139,144,145,178).  
Future polyoxometalate chemistry can be expected to progress towards even more complex 
conjugation steps wherein natural biological molecules like carbohydrates, steroids and peptides 
can be incorporated . It can be therefore envisaged that subsets of transcription factor interaction 
domains or whole peptides can be conjugated with synthetic Dawson polyoxometalates to target 
regulatory or DNA binding domains in a truly specific way. For example it can be conceived that 
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designing specific recognition peptides capable of interacting with the Sox2-HMG surface could 
be linked with the inorganic framework of Dawson-POMs to potentially achieve a very targeted 
inhibition of Sox2-HMG.  
The only comparable effort to target systematically the DNA binding domains of transcription 
factors with a core inhibition chemistry is the usage of nucleic acid decoy-like aptamers (65). 
Just as with POMs, however aptamers suffer from the disadvantage that introducing large 
charged molecules into cells can be a variable process (65). Bulk production of aptamers could 
also be expensive (100-500 USD/g) as compared to synthesis of polyoxometalates which 
generally require only cheap salts like sodium molybdate/tungstate, phosphoric acid and an 
organic substrate of interest to link to the inorganic framework (193). 
Overall, the inhibitory mechanism of the Dawson-POM demonstrated here could eventually 
spawn the development of novel drugs that could incorporate strategies from the POM based 
inhibition chemistry of TFs, to specifically combat aberrant gene expression. The study has 
demonstrated that challenging molecular architectures like the DNA binding domains of 
transcription factors are tractable drug targets and that Dawson polyoxometalates can be 
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FoxA1 element (19bp) 
5’(FAM)-TGCCAAGTAAATAGTGCAG-3’ 
              
AP2-HPSE(19bp) 
5’ (FAM)-AAAGTGCCCAGAGCCCATG-3’  
 
 




















Figure. A saturated complex of 1nM DNA and 50 nM Sox2 was competed by addition of 
unlabeled CCND1 in the presence of varying concentrations of DMSO. The assay shows 









Appendix table 1.Primary hits identified from the screening 
NSC Molecular formula Mol.wt (g mol-1) Composite 
Z-score 
Reproducibility 
3064 C16H16N4O4 328 -7.619112165 -0.999797067 
25678 C18H15NO2 277 -6.060548322 -0.999716549 
45536 C16H11FN2O 266 -5.779801696 -0.999029388 
7572 C13H14N2O3S 278 -5.64302035 -0.998102966 
13973 C15H15N3.ClH 274 -5.638405917 -0.999735078 
605756 C13H11N3.8/5ClH 268 -5.624649541 -0.999886179 
403374 C8H9ClN4S 229 -5.606006746 -0.999815322 
12644 C9H12AsNO5 289 -5.603219665 -0.999990452 
117197 C14H13N5O3 299 -5.600512132 -0.998941935 
6731 C17H18O2 254 -5.591618633 -0.999922619 
373535 C12H12N2O3 232 -5.577978008 -0.999994223 
337851 C40H45N3O6S 696 -5.400999762 -0.999360347 
402083 C13H10N2O2 226 -5.350655033 -0.999934197 
660301 C10H9ClN2O2 225 -5.238020222 -0.998603973 
503425 C7H4ClNS2 202 -5.20617902 -0.999999266 
107022 C12H6O8 278 -5.13495199 -0.998360358 
667251 C17H16N2 248 -5.090616878 -0.998804377 
637308 C12H10N2O4 246 -4.380567029 -0.999965859 
622124 K6Mo18O62P2 3015 -4.06659908 -0.999486466 
99027 C10H7BrO2 239 -4.065993889 -0.999940475 
663996 C14H18N2O2 246 -4.065768749 -0.998114385 
82025 C14H11N3O6 317 -4.032896914 -0.9978595 
638352 C32H22N6O14S4.4Na 935 -3.999039966 -0.999799055 
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375392 C14H14N2 210 -3.882518672 -0.999740793 
34931 C34H24N4O14S4.4Na 933 -3.86807345 -0.999933053 
261726 C6H6N4O 150 -3.863854659 -0.999291024 
191389 C17H17NO 251 -3.795361323 -0.996068431 
616232 C6H12Br2O4 308 -3.75795373 -0.999874457 
659437 C10H7N3O4 233 -3.735222308 -0.99862276 
636132 C18H16N2O2 292 -3.733185925 -0.999997171 
63878 C9H13N3O5.ClH 280 -3.730940183 -0.999679245 
638080 C10H8N2O4 220 -3.723164705 -0.997994358 
688795 C12H12O4 220 -3.698398749 -0.99837388 
635441 C11H12N2O3 220 -3.664808403 -0.999853742 
80396 C12H7F3O2S 272 -3.658615322 -0.99998664 
7833 C14H10N2O2 238 -3.605805426 -0.999583929 
5200 C10H10N6O 230 -3.571323176 -0.999620574 
295156 C7H8O2 124 -3.565955577 -0.999960147 
285166 C9H7NO 145 -3.533904375 -0.999128027 
283162 C9H18N6O3 258 -3.519693925 -0.999035146 
606532 C7H7N3O5 213 -3.477039911 -0.999241966 
31702 C18H13N3O 287 -3.345152209 -0.998497235 
157004 C18H16N2O5 340 -3.229268921 -0.999830257 
28002 C18H14N.Cl 280 -3.228235201 -0.999982325 
4170 C11H8O2 172 -3.223886845 -0.999923013 
659501 C13H10N2O2S 258 -3.12676136 -0.999529284 
637993 C22H26N4O2.2ClH 451 -3.062857238 -0.995853966 
1771 C6H12N2S4 240 -3.058732054 -0.9949141 
672425 C19H14N2O4.HNO3 397 -3.046819292 -0.998450148 
32946 C5H12N8.2ClH 257 -3.014661188 -0.997342004 







Figure. 8nM of Pax6 was added to 1nM of a fluorescently labeled Pax6 consensus DNA 
sequence. Addition of unlabeled Pax6 consensus DNA sequence (100nM DNA element) serves 
as the positive control for complete inhibition of the Pax6-fluorescein labeled DNA complex. 
Addition of 200nM of Dawson POM to the previously bound Pax6-DNA complex has no effect 






















Figure. An expanded  snapshot of the docked configuration of the Dawson-POM K6[P2Mo18O62] 
with Sox2. Hydrogen  bonds and electrostatic interactions less than 3.5Å are shown in red dots. 











The inhibition of Pax6 by 15 different polyoxometalates studied using EMSA. DNA binding 
activity was estimated from maximally bound Pax6-DNA (no POM) and free DNA gel-shift 




Appendix Table 2. P-value of two-tailed, unpaired T-test (assuming equal variance) on residual DNA binding activities of 15 
TFs upon K6[P2Mo18O62] treatment.  P-values less than 0.05 were taken as being statistically significant. 
 
 Sox2 Sox4 Sox5 Sox6 Sox7 Sox8 Sox9 Sox10 Sox11 Sox17 Sox18 AP2 REST Foxa1 
Sox2 1 0.0808 0.9486 0.3716 0.011 0.7415 0.1388 0.3531 0.1933 0.4389 0.0292 0.3049 0.0967 0.9152 
Sox4  1 0.0473 0.0074 0.1832 0.0881 0.337 0.1934 0.938 0.6116 0.6237 0.0053 0.8675 0.0377 
Sox5   1 0.2873 0.005 0.6408 0.0597 0.2383 0.1557 0.3944 0.0125 0.2081 0.0669 0.8194 
Sox6    1 0.0007 0.1248 0.001 0.0215 0.0576 0.1934 0.001 0.7134 0.0175 0.0805 
Sox7     1 0.0087 0.0191 0.0158 0.2947 0.1918 0.2815 0.0005 0.3214 0.0029 
Sox8      1 0.1483 0.4683 0.2354 0.5354 0.0249 0.0851 0.1115 0.7349 
Sox9       1 0.4403 0.5964 0.972 0.0807 0.0002 0.3488 0.0266 
Sox10        1 0.4049 0.7898 0.0546 0.0123 0.2167 0.2212 
Sox11         1 0.7045 0.6773 0.0493 0.8412 0.1613 
Sox17          1 0.4212 0.1732 0.5587 0.4273 
Sox18           1 0.0006 0.8242 0.0067 
AP2            1 0.014 0.0347 
REST             1 0.0623 
Foxa1              1 
 
